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ABSTRACT 
Researchers have achieved an experimental breakthrough in the simultaneous 
use of two or more agents for treating cancer, known as combination therapy. 
Many times the combination of chemotherapeutic drugs is useful because the two 
compounds generally act in different phases of the cell cycle and with different 
mechanisms of action. Usually one of them is a so called “standard” chemotherapic 
acting on cell cycle progression and the other is a “new generation” drug with a 
specific molecular target.   
My work concerns this specific field of study. It contributed to characterize 
the cellular and molecular response of four tumor cell lines to combination of two 
chemotherapic compounds: Camptothecin that is a well known topoisomerase I 
inhibitor and Roscovitine, a CDK inhibitor recently used for cancer treatment. In 
vitro treatment with two drugs alone or in combination revealed that Roscovitine, is 
able to protect cells from Camptothecin-induced DNA damage and to produce a 
sort of chemoresistance. The human cell lines used in this work A549 (p53+/+) and 
H1299 (p53-/-) derived from Non Small Cells Lung Cancer and HCT116 (p53+/+ o 
p53-/-) from colon cancer.  
 Roscovitine  and Camptothecin have different effects on cellular cycle. Cells 
treated with Roscovitine partially accumulate in the G2 phase, Camptothecin, 
instead, leads to different effects according to p53 status: lines p53+/+ arrest in S 
phase, lines p53-/- arrest in G2 phase. The combined treatment determines ulterior 
effects: in p53+/+ cells we observe an increase in G1 phase; in p53-/- we find a block 
in S phase. Clonogenic assays performed 10 days after the treatment suggest that 
cells incubated with  the two drugs together generate more colonies than which 
incubated with Camptothecin alone. After the combined treatment, we found a 
consistent decrease in the number of senescent cells  (40%~) (flatten morphology 
and  ß-galattosidase positivity) compared with that obtained after single treatment 
with Camptothecin. According to this observation, must be noted that we can see a 
minor activation of p53(less phosphorylation in ser 15) in p53 positive cells and a 
decrease in p21 expression  in p53 negative cells. Further results indicate that the 
main target of Roscovitine in our model is CDK2 and that the response to the DNA 
damage involves PCNA and Cdc6 proteins. Roscovitine seems to be able to 
activate more effectively DNA damage sensors previously induced by 
Camptothecin. This activation may be responsible of an anticipated cell cycle 
block, a more effective reply to the damage, a prolonged surviving  and a minor 
induction of cellular senescence.  
 
1. INTRODUCTION 
 
1.1 The cell cycle control proteins 
The cell cycle is controlled by numerous mechanisms ensuring correct cell 
division and DNA replication. The transition from one cell cycle phase to another 
occurs in an logical and organized way and is regulated by different proteins. In a 
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mitosis-competent cell, the accurate entry and proper progression through the cell 
cycle are monitored by a series of checkpoint controls. Key regulatory proteins of 
these restriction points are the cyclin-dependent kinases (CDK), a family of 
serine/threonine kinases that are activated at specific phases of the cell cycle 
(Fig.1). Until now, nine CDK have been identified. Five of them are active during 
the cell cycle i.e. entering G1 phase (CDK3) (Ren 2004 Cell), during G1  phase 
(CDK4, CDK6 and CDK2), S phase (CDK2), G2 phase and M phase (CDK1). 
CDK7 acts as CDK activating kinase with its her catalytic subunity cyclin H 
(Fisher and Morgan 1994). CDK8 (Donner 2007) and CDK9 (Marshall 2006) seem 
to be transcriptional co-regulators. CDK proteins levels remain stable during the 
cell cycle, in contrast to their activating proteins, the cyclins. Cyclin proteins levels 
rise and fall during the cell cycle and, in this way, the function of CDK is 
periodically activated. (Evans 1983). Different cyclins are required at different 
phases of cell cycle. The three D type cyclins bind to CDK4 and to CDK6 and are 
essential for entry in G1 (Sherr 1994). Another G1 cyclin is cyclin E which 
associates to CDK2 to regulate progression from G1 into S phase (Ohtsubo 1995). 
Cyclin A binds with CDK2 and this complex is required during S phase (Girard 
1991). In late G2 and early M cyclin A complexes with CDK1 to promote entry 
into M phase. Mitosis is further regulated by cyclin B in complex with CDK1. 
(King 1994).  
 In addiction to cyclin binding, CDK activity is also regulated by 
phosphorylation on conserved threonine and tyrosine residues. These 
phosphorylations induce conformational changes and enhance the binding of 
cyclins (Jeffrey 1995). Dephosphorylation on these sites by the enzyme Cdc25 is 
necessary for progression through the cell cycle (Lew 1996). CDK activity can be 
also negatively controlled by inhibitory proteins called CDK inhibitors (CKI) 
which bind to CDK alone or to the CDK-cyclin complex. Two distinct families of 
CDK inhibitors have been identified, the INK4 family and the Cip/Kip family 
(Hirai 1995). The INK4 family includes p15 (INK4b), p16 (INK4a), p18 (INK4c), 
p19 (INK4d), which specifically inactivate G1 CDK (CDK4 and CDK6). This 
family of proteins form stable complex with CDK before cyclin binding, 
preventing association with cyclin D (Carnero 1998). The second family of 
inhibitors, the Cip/Kip includes p21 (Waf1, Cip1 ), p27 (Cip2), p57 (Kip2). These 
inhibitors inactivate cyclin/CDK complexes (Polyak 1994). CDK’ s targets proteins 
are key proteins for cell cycle progression. Among them the most important are the 
retinoblastoma tumor suppressor gene (pRb), CDK’s own regulators WEE1 and 
Cdc25, and cytoskeletal proteins such as nuclear lamins, microtubules and 
vimentin which are required for correct mitosis (Heald e McKeon 1990;)  
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Fig. 1 Schematic representation of major CDK/cyclins complexes and CDK inhibitors 
involved in the progression of the cell cycle. These protein complexes determine cell cycle 
progression or block according to the  balance between anti-proliferative and mitotic  signals. 
 
1.2 Cell cycle checkpoints 
The cell cycle proceeds by a defined sequence of events where late events 
depend upon completion of early events. The aim of the dependency of events is 
to distribute complete and accurate replicas of the genome to daughter cells. To 
monitor this dependency, cells are equipped with the checkpoints that are set at 
various stages of the cell cycle (Fig.2). The first of this control points is the so 
called “restriction point”. This is defined as a point of no return in G1 following 
which the cell is committed to enter the cell cycle (Kaufmann 1995). This 
checkpoint depends on external conditions such as serum concentration in the 
medium of culture. If the environment is not indicated for division, cell enter a 
phase of quiescence called G0 in which it remains until the conditions become 
favourable to division. But the most important control that cell makes before 
duplication is DNA integrity. When cells have DNA damages that have to be 
repaired, then activate DNA damage checkpoint that arrests cell cycle. According 
to the cell cycle stages, DNA damage checkpoints are classified into at least three 
checkpoints: G1/S (G1) checkpoint, intra-S checkpoint, and G2/M checkpoint. 
Upon perturbation of DNA replication by drugs that interfere with DNA synthesis, 
DNA lesions, or obstacles on DNA, cells activate DNA replication checkpoint that  
arrests cell cycle at G2/M transition until DNA replication is complete. There are 
other two checkpoints called Spindle checkpoint and Morphogenesis checkpoint. 
The spindle checkpoint arrests cell cycle at M phase until all chromosomes are 
aligned on spindle. This checkpoint is very important for equal distribution of 
chromosomes. Morphogenesis checkpoint detects abnormality in cytoskeleton and 
arrests cell cycle at G2/M transition. At the G1/S checkpoint cell cycle arrest is 
mainly p53 dependent and the DNA damage lead to a rapid induction of the 
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protein. The G2/M checkpoint is, instead, p53 independent because the arrest of 
the cycle is obtained by maintaining CDK1 in its inhibited form throught 
inhibitory phosphorylation or by sequestration outside the nucleus (Stark 2004).    
The mechanisms of S phase DNA damage checkpoint are less understood 
but some studies demonstrated suppression of both the initiation and elongation 
phases of DNA replication. (Painter 1986; Paulovich & Hartwell 1995) The intra-
S-phase checkpoint, in fact differs from the G1/S and G2/M checkpoints since its 
activation don’t lead to a cell cycle block but only to a delay. This checkpoint, in 
fact, has to recognize and deal with replication intermediates and stalled 
replication forks. Also, in the S phase, another checkpoint that prevents 
transmission of unreplicated DNA is active. This process inhibits mitosis while 
DNA replication is ongoing or blocked. The signal for this checkpoint is 
represented by unreplicated DNA rather than DNA damage. 
 
 
Fig. 2 Schematic representation of the cell cycle. DNA damage triggers activation of these 
cell cycle checkpoints, which can lead to an arrest at the G1/S, intra-S, or G2/M phase (indicated 
in red). During cell cycle arrest, the DNA damage can be repaired. 
 
1.3 The DNA damage 
A wide diversity of lesions (Fig.3) caused by environmental agents such as 
ultraviolet (UV) radiation in sunlight, ionizing radiation, and numerous genotoxic 
chemicals can arise in the DNA. In addition, the genome is also attached by 
internal products of normal cellular metabolism, such as reactive oxygen species 
(ROS; i.e., superoxide anions, hydroxyl radicals, and hydrogen peroxide) derived 
from oxidative respiration and products of lipid peroxidation. These agents can 
cause a variety of damages in the DNA. 
    The DNA damage response during any phase of the cell cycle has the 
same pattern. After the detection of DNA damage by sensor proteins, signal 
transducer proteins transduce the signal to effector proteins (Fig.3). These effector 
proteins launch a cascade of events that causes cell cycle arrest, apoptosis, DNA 
repair, and/or activation of damage induced transcription programs. The most 
important players in the early response to DNA damage consists of two kinases 
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called Ataxia Telangiectasia (AT) Mutated (ATM) and ATM and Rad3 Related 
(ATR). Ataxia telangiectasia is an autosomal recessive disorder caused by 
mutated ATM, characterized by immunodeficiency, neurological disorders, and 
high cancer susceptibility. ATR was identified later on basis of sequence and 
functional homology to ATM. 
 These kinases phosphorylate p53 at serine 15 in response to DNA damage, 
resulting in the stabilization of the protein and subsequently amplifying the 
downstream p53 cascade and obtaining p21 blocking the cell cycle (Siliciano et al. 
1997). The ATM and ATR proteins belong to the phosphatidylinositol 3-kinase-
like (PIKK) family of serine/threonine protein kinases. This family also includes 
DNA protein kinase (DNA-PK). DNA-PK has an important role in G1/S 
checkpoint and seems to be a DNA double strand break repair enzyme. (Durocher 
& Jackson 2001). 
ATM appears to be the primary player in response to ionizing radiation. 
Recent results suggest that the Rad50/Mre11/Nijmegen Breakage Syndrome 1 
(NBS1) complex and Rad17 protein function as the DSBs sensor for ATM 
(Williams 2007). ATR, instead, is more important in response to UV radiation and 
replication inhibitors such as hydroxyurea (HU). 
Other candidate DNA damage sensors are three proteins Rad9, Hus1, and 
Rad1 that form a ring structure (the so called “9–1–1” complex) that can encircle 
the damaged DNA and is expected to form a scaffold for downstream checkpoint 
and repair proteins (Jaco 2006). 
All these sensors proteins are able to activate different downstream effectors 
such as  the two checkpoint kinases Chk1 and Chk2. 
Chk1 and Chk2 are, like ATM and ATR, serine/threonine protein kinases and 
phosphorylate targets that eventually result in the cell cycle arrest. The Double 
Strands Breaks (DSBs) signal sensed by ATM is transduced by Chk2, and the UV 
damage signal sensed by ATR is transduced by Chk1, although there is some 
overlap and redundancy between the functions of these two proteins. Chk1 and 
Chk2 transfer the signal of DNA damage to the phosphotyrosine phosphatases and 
cell division cycle proteins Cdc25A, Cdc25B, and Cdc25C. Phosphorylation of 
Cdc25A–C by Chk1 or Chk2 inactivates Cdc25A–C, whereas unphosphorylated 
Cdc25A–C promotes the G1/S and G2/M transition by dephosphorylating the 
cyclin dependent kinases (CDKs) directly involved in cell cycle transition. 
The exact pathway of cell cycle arrest depends on the kind of damage. DNA 
DSBs lead to phosphorylation of ATM that subsequently phosphorylates Chk2. 
Single-strand gaps result in the activation of Rad17 or the 9–1–1 complex, and 
ATR, which leads to phosphorylation of Chk1. Subsequent phosphorylation of 
Cdc25A by Chk1 or Chk2 causes inactivation of this protein by nuclear exclusion 
and ubiquitin-mediated proteolytic degradation, leading to G1 arrest. ATM and 
ATR also phosphorylate p53, which leads to stabilization and accumulation of the 
p53protein and promotes its transcription factor activity. Two pathways mediate, 
instead, the intra-S-phase checkpoint. Firstly, the ATM/ATR–Chk2/Chk1–
Cdc25A–CDK2 pathway is more or less similar to the G1/S checkpoint. In the S 
phase, this pathway delays replication (by blocking the loading of Cdc45 onto 
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chromatin that in turn attracts DNA polymerase-a into prereplication complexes) 
and, as a consequence, extends the DNA replication time, allowing DNA repair to 
take place. The second pathway involves Nbs1 which is phosphorylated by ATM 
together with Chk2, leading to a cascade involving also Mre11- and Rad50-like 
initial DSBs recognition, which plays a role not only in cell cycle arrest but also in 
activating the repair processes. When cells encounter DNA damage in G2, the 
G2/M checkpoint stops the cell cycle in order to prevent the cell from entering 
mitosis. As in the G1/S checkpoint, the kind of DNA damage determines the 
pathway that will be activated: ATM–Chk2–Cdc25 for DSBs and ATR–Chk1–
Cdc25 for DNA lesions such as those created by UV light. Besides down-
regulating Cdc25A, both Chk1 and Chk2 upregulate WEE1 by phosphorylation, 
which together control Cdc2/CyclinB activity. This latter complex promotes 
G2/M transition under normal circumstances, and inactivation blocks the cell 
cycle when damage  occurs in G2. 
 
SENSORS
EFFECTORS
TRANSDUCERS
MEDIATORS
RAD 50
MRE11
NBS1
RAD 17
HUS1
RAD1
RAD9
ATM
DNA DAMAGE
ATR
BRCA1 TOPBP1
CHK2 CHK1
G1 S G2 M
p53 Cdc25
 
 
 Fig. 3 Simplified representation of the DNA-damage-induced checkpoint response. After 
the detection of a given damage by sensor proteins, this signal is transduced to the effector proteins 
Chk1 and Chk2 via the transducer proteins ATR and ATM. Depending on the phase of the cell 
cycle in which the cell is, this can lead to activation of p53 and inactivation of CDC25, which 
eventually leads to cell cycle arrest.  
 
1.4 DNA repair 
The DNA damage has not only to be prevented, but also to be repaired when 
occurred. As there are many different lesions possible, different types of repair 
pathways have evolved. Important pathways in mammalian cells include base 
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excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), 
and DSBs repair (Fig.4). 
BER is the main guardian against damage due to cellular metabolism. Base 
damages are generated by ROS, ionizing radiation, and indirectly also by UV 
radiation (via generation of ROS) or can be the result of various chemicals like 
chemotherapeutic drugs (e.g., adriamycin, mitomycin C, and psoralen). In BER, 
the damaged base is removed by different DNA glycosylases (depending on the 
damage) and APE1 endonuclease. This results in an abasic site, from which both 
ends are trimmed by poly(ADP-ribose) polymerase and polynucleotide kinase to 
facilitate repair synthesis. 
NER is the most important repair system to remove damage that distorts the 
normal architecture of the DNA helix and bulky DNA lesions that can be caused 
by UV radiation (thymidine dimers), chemicals, or ROS. Disruption of the DNA 
helix interferes with base pairing and hinders transcription and normal replication. 
The repair of damaged DNA involves at least 30 polypeptides within two different 
sub-pathways of NER known as transcription-coupled repair (TCR-NER) and 
global genome repair (GGR-NER). (Reardon and A. Sancar 2005). Repair is much 
more efficient in actively transcribed genes than in the overall genome, and the 
two pathways differ only in the initial DNA damage recognition step. NER 
includes a lot of different proteins but  the most important of them are encoded by 
seven xeroderma pigmentosum (XP) complementation groups, XPA to XPG 
genes.  
Replication errors by DNA polymerase- α can result in mismatched bases 
(A–G or C–T). The mismatch repair (MMR) process begins with the proteins 
Msh2–6 that recognize and bind to the mismatched base pairs Subsequently, the 
mismatched strands are cleaved, and the segment from the cleavage site to the 
mismatch is removed by an exonuclease. DNA polymerase-α fills in the single-
strand gap.  
The described repair systems are efficient only with damaging agents that 
cause single strand lesions but the most dangerous damages that occurs on DNA 
are DSBs.   
DSBs are a very genotoxic type of DNA damage. Because both strands of 
the DNA double helix are broken, chromosomal fragmentation, translocation, and 
deletions can easily occur and rapid repair is crucial. DNA DSBs can be caused by 
ionizing radiation, ROS, and chemotherapeutic drugs and can arise during 
replication of a single-strand break.  
In recent studies, it was shown that one of the first responses of eukaryotic 
cells to DSBs is the extensive phosphorylation of a member of the histone H2A 
family, H2AX, by the PI3-like kinases ATM, ATR and DNA-PK. 
In order to repair DNA DSBs, two distinct pathways have evolved: 
Homologous Recombination (HR) and Non Homologous End Joining (NHEJ). 
The two main differences between these pathways are the requirement for 
extensive DNA homology on the sister chromatid in HR and the accuracy of 
repair. HR is mediated by the Rad52  group that includes the Rad51, Rad52, and 
Rad54 genes.  After introduction of the DSB, Rad51, which is the central protein 
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in HR, searches the genome for an intact copy of the broken DNA on the sister 
chromatid. In this way the missing information on the broken strand is copied in, 
and the damage is repaired without loss of genetic information. 
 In NHEJ, on the contrary, there is no need for homology. The two ends of 
the broken double helix are directly ligated together by the DNA ligaseIV/Xrcc4 
complex. Other proteins involved in this pathway are the Ku70/80 heterodimer, 
DNA-PKCS, and the Rad50/Mre11/NBS1 complex. NHEJ is less accurate and 
might give rise to deletions. 
Although both DSB repair pathways are operational in mammals, their relative 
contribution differs depending on the stage of the cell cycle or the cell type. For 
HR to occur, there is a need for a sister chromatid, which is not produced until the 
S phase. For this reason, HR can only take place in dividing cells that are in the S 
or G2 phase. Cells in G0 and G1 or terminally differentiated cells mainly rely on 
NHEJ. A number of the previously mentioned DNA DSB repair proteins (for 
instance, Rad51, Rad54, and the MRN complex) and γ-H2AX relocate into 
nuclear foci after induction of DNA damage. These foci are believed to play an 
important role as DNA damage repair factories, harboring thousands of repair and 
cell cycle checkpoint proteins, although their exact role remains to be elucidated.  
 
 
Fig. 4 Summary of the most common types of DNA lesions that can be caused by 
exogenous or endogenous damaging agents. They may affect a single strand or both strands of the 
DNA. The assumed repair pathway that operates on the various lesions is also indicated. 
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1.5. Chemotherapeutic Drug 
 
1.5.1 CDK inhibitors 
CDK inhibitors are a heterogeneous group of compounds that are able to 
inhibit CDKs involved in the cell cycle, transcription or neuronal functions. CDK 
inhibitors are chemically diverse, low-molecularweight (< 600 Da), hydrophobic 
heterocycles. CDK inhibitors compete with the ATP for the ATP binding site. No 
CDK inhibitor has been shown to compete with the target proteins of CDKs. The 
first CDK inhibitors were the natural products flavopiridol, butyrolactone, 
indirubin and staurosporine with its 7-hydroxy-derivative UCN-01. Later, purine 
and pyrimidine analogues were produced: olomoucine, R-Roscovitine, 
CGP74514A, BMS-387032, purvalanol B, the pyridopyrimidines (PD0183812 
and PD0332991) and other chemical derivatives including the sulphonamide 
E7070.   
According to their different specificity these inhibitors may be subdivided in three 
different groups: CDK2, 1 and 5 inhibitors; CDK4 and 6 specific inhibitors; pan 
CDK inhibitors (fig. 5). These compounds however are not so selective. In fact it 
was demonstrated that they inhibit not only CDKs but also other kinases, 
including the MAP kinases Erk1 and Erk2 (Schulze-Gahmen, 1994). 
Flavopiridol (Flavo) is one of the best characterized CDK inhibitors. It is a semi-
synthetic flavonoid derived from the natural alkaloid, rohitukine, originally 
isolated from leaves and stems of Amoora rohituka (Schang, 2005). Flavo was 
initially developed as an inhibitor of EGFR and protein kinase A (Sattler 2004). 
However, the compound was found to inhibit CDKs at far lower concentrations 
than those required for EGFR or protein kinase A inhibition. Then it was revealed 
that at nanomolar concentrations it inhibits CDK1, 2, 4, 9 and likely 6 (Schang, 
2005; Senderowicz and Sausville, 2000). Flavo induces cell cycle arrest in G1 in 
vivo and in vitro, perhaps by inhibiting CDK1 and 2. It is cytotoxic to cells 
synthesizing DNA and causes apoptosis (Carlson, 1999). 
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From Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 
2006  
 
Fig. 5  Small-molecule cyclin-dependent kinase (cdk) inhibitors may be classified based on effects 
on the cell cycle cdks. Pan-cdk inhibitors, including flavopiridol inhibit cdks 4/6, 2, and 1. Other 
compounds are highly selective inhibitors of cdk4/6. Several other compounds inhibit cdk2 and 
cdk1 more selectively, 
 
Another well-characterized CDK inhibitor of the first generation is UCN-01 
(7-hydroxystaurosporine). UCN-01 is an alkaloid from Streptomyces bacteria, 
derived from staurosporine. Initially discovered to target CDK1 and CDK2, it is 
now known to have pan-CDK inhibitory activity, as well as promoting p53-
independent apoptosis by targeting Chk1 and Chk2 (Wang et al., 1996). In in vitro 
assays UCN-01 causes cell cycle arrest and apoptosis (Akiyama et al., 1997). 
The search for specific pharmacological CDK inhibitors resulted in the discovery 
of 6-aminopurines, semi-specific but not very potent CDK inhibitors 
(Shchemelinin et al.). Compounds containing a purine-like ring (purine-type CDK 
inhibitors) include Roscovitine, olomoucine, the purvalanols and related 
compounds. Purine-type CDK inhibhitors preferentially inhibit CDK1, 2, 5 and 7, 
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but not CDK4, 6, or 8 (Schang, 2005). Olomoucine (Olo) was the first specific 
and relatively potent CDK inhibitor discovered. 
More potent but equally specific Roscovitine (Rosco) was then discovered 
(Schang, 2005). R-Roscovitine (CYC202 or Seliciclib) is an orally bioavailable 
purine analogue that competes for the ATP-binding site of CDK2/cyclin E, 
CDK4/cyclin D1, CDK7/cyclin H, CDK9/cyclin T1 (McClue et al., 2002). Rosco 
inhibits MDM2 expression and thus blocks p53 degradation. 
Studies in the Lovo colorectal carcinoma cell line showed that Roscovitine 
induced cell death in all stages of the cell cycle. In xenograft studies, Roscovitine 
administered orally or intraperitoneally induced tumour growth delay (McClue et 
al., 2002). The anti-tumour efficacy of Roscovitine has been tested in a panel of 
77 human tumour xenografts in order to find out which tumour types are sensitive 
to Rosco. A dose-dependent anti-tumour activity of CYC202 has been detected. 
CYC202 was most active in inhibiting the proliferation of colon, non-small-cell 
lung, breast and prostate human cancer xenografts (de Bono, 2006). 
CDK inhibitors are apparently well tolerated, in animal experiments and human 
clinical trials against cancer.  
Many other non-purine related CDK inhibitors have been designed, 
including other flavonoids, paullones, indirubines and aloisines. The development 
of novel CDK inhibitors still continues and new compounds are continuously 
added to this group (Schang, 2005). 
A growing number of CDK inhibitors representing multiple chemical 
classes currently are in clinical trial. Trials using load/infusion schedules, 
designed to achieve and sustain micromolar levels, are more mature in 
hematologic malignancies and are just beginning evaluation in solid tumors. In 
solid tumor studies, flavopiridol, seliciclib, and BMS-387032 (SNS-032) have 
been the most extensively tested alone or in combination with other conventional 
chemotherapeutic drugs. 
Flavopiridol and Seliciclib are currently used in phase II clinical trial for 
CLL, lymphoma, and multiple myeloma. For flavopiridol, novel drug schedules 
appear to be overcoming pharmacokinetic barriers. Initial trials, both in 
hematopoietic malignancies and solid tumors, used 24- to 72-hour continuous 
infusions to reflect preclinical observations that prolonged exposure enhanced 
apoptotic effects in vitro and repeated low-concentration drug treatment 
demonstrated antitumor activity in vivo (Senderowicz 1998). 
Flavopiridol and Seliciclib are also used in combination with a lot of 
chemotherapeutic drugs. In particular combination with paclitaxel and docetaxel 
have been studied in phase I and II for breast and gastric carcinomas, combination 
with adriamycin and flavopiridol for osteosarcoma and combination with 
gemcitabine for non small cell lung cancer and colon cancer. (Bible 1997; Fornier 
2007). 
 
1.5.2 Topoisomerase I inhibitors 
The double-helical configuration that DNA strands naturally reside in makes them 
difficult to separate, and yet they must be separated by helicase proteins if other 
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enzymes are to transcribe the sequences that encode proteins, or if chromosomes 
are to be replicated. Otherwise identical loops of DNA having different numbers 
of twists are topoisomers, and cannot be interconverted by any process that does 
not involve the breaking of DNA strands. Topoisomerases catalyze and guide the 
unknotting of DNA. Topoisomerases are divided into type I and II. Type I 
enzymes cleave only one strand of duplex DNA whereas type II enzymes cleave 
both strands. Type I topoisomerases (Fig.6A) are further subdivided into type IA 
and IB. Type IA enzymes cleave the DNA by forming a 5′-phosphotyrosyl 
covalent bond and relax DNA supercoiling by a strandpassing mechanism, 
whereas type IB enzymes form a covalent bond with the 3′ end of the DNA, and 
relax DNA by controlled rotation (Fig. 6B).  
A            B                  
 
Fig. 6A Crystallographic representation of  Topoisomerase I enzyme bound to DNA. The enzyme 
is able to cleave only one strand of DNA. 6B Mechanism of action of Topoisomerase I enzyme. It 
cleaves the DNA by forming a 5′-phosphotyrosyl covalent bond and relax DNA supercoiling by a 
strandpassing mechanism, whereas type IB enzymes form a covalent bond with the 3′ end of the 
DNA, and relax DNA by controlled rotation.  
   
Because of the size and mass of the replication and transcription complexes 
it is plausible that such complexes do not rotate freely around the DNA helix. In 
addition, because of the limited free rotation of the DNA domain flanking a given 
replication or transcription complex, DNA supercoiling is generated by DNA 
metabolism. Therefore, DNA tends to be overwound (positively supercoiled) 
upstream of replication or transcription forks and underwound (negatively 
supercoiled) downstream of these forks. 
Such supercoiling tightens the DNA duplex and needs to be relaxed by 
topoisomerases (TOP1 and TOP2). 
Mammalian TOP1, TOP1mt TOP2α and TOP2β can relax both positive and 
negative supercoiling. Therefore, TOP1 enzymes tend to be concentrated in 
supercoiled chromatin regions (particularly in association with transcription or 
replication complexes). DNA topoisomerases are particularly vulnerable to 
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topisomerase inhibitors during their cleavage intermediate step. TOP1 cleavage 
complexes (TOP1ccs) are normally so transient that they are not detectable, but it 
is these complexes that are specifically and reversibly trapped by pharmaceutical 
compounds. High levels of cellular TOP1ccs can accumulate owing to DNA 
modifications and finally to apoptosis.  
For these reason Topoisomerase 1 is the target of some potent 
chemotherapeutic drugs. Camptothecin was the first of these compounds to be 
developed in the mid 1970s. It was first isolated from the bark of the Chinese tree, 
Camptotheca acuminate. It was discovered and developed by the US National 
Cancer Institute (NCI). TOP1 is the only cellular target of this drug. Camptothecin 
carboxylate was tested clinically and showed anticancer activity, but was 
discontinued because of its side effects (Wall et al.1995). It was not until after the 
discovery that TOP1 was the cellular target of Camptothecin that the water-
soluble derivatives of Camptothecin — topotecan and irinotecan (also known as 
CPT-11) — were successfully developed.  
Because TOP1 inhibitors bind reversibly to TOP1ccs, and TOP1 readily 
religates the cleaved DNA after drug removal, TOP1 inhibitors do not directly 
damage DNA. It is TOP1 itself that damages DNA in connection with DNA-
helix-tracking processes — primarily replication and transcription. As TOP1 
religation activity is slowed down by the drugs, replication and transcription 
complexes ‘catch up’ and ‘collide’ with the TOP1–DNA cleavage complexes, 
thereby generating irreversible TOP1 covalent complexes as the 5′ end of the 
nicked DNA template becomes misaligned with its substrate. As TOP1 religation 
activity is slowed down by the drugs, replication and transcription complexes 
‘catch up’ and ‘collide’ with the TOP1–DNA cleavage complexes, thereby 
generating irreversible TOP1 covalent complexes as the 5′ end of the nicked DNA 
template becomes misaligned with its substrate. Replication-fork collision is the 
primary cytotoxic mechanism of TOP1 inhibitors in dividing cells (Fig.4). Indeed, 
cancer cells in culture tend to be resistant to Camptothecin when they are outside 
of S-phase (Horwitz 1973; O’Connor 1991) or when replication is arrested at the 
time of Camptothecin treatment (Holm 1989; Hsiang 1989 ). Moreover, like other 
cell-cycle-specific agents, Camptothecin is increasingly cytotoxic with increasing 
time of drug exposure. Camptothecin kills fewer than 50% of cells when they are 
exposed to the drug for less than 1 hour. This is different from TOP2 inhibitors, 
which can be highly cytotoxic (over 90%) even in the absence of active 
replication (Holm 1989). 
As for most other anticancer agents, the prescription of TOP1 inhibitors is 
currently based on the cancer histology  and tissue of origin. Irinotecan is 
approved for colon carcinomas, whereas topotecan is approved for ovarian 
cancers, although both drugs target TOP1 in a similar way. The different 
indications have been determined empirically over the course of clinical trials, 
rather than by the molecular characteristics of the tumours. 
The search for non-Camptothecin TOP1 inhibitors was initiated immediately 
after the discovery that TOP1 was the cellular target of Camptothecins. The 
screening of chemical libraries and natural products with purified TOP1 and 
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isolated DNA substrates led to the discovery of various TOP1 inhibitors (), 
including the indolocarbazoles and phenanthroline derivatives. They seem to be 
more effective than the classic Camptothecins but several studies indicate that, 
although they are therapeutically effective, they are not curative as single agents. 
Several approaches need to be considered to improve the effectiveness of TOP1 
inhibitors. First, the development of new inhibitors with activity against different 
cancers, improved pharmacokinetics and lower toxicity are needed. Second, 
further investigation of the molecular determinants of drug activity in model 
systems should lead to the development of molecular tools to classify tumours on 
the basis of whether they have a molecular network matching drug-specific 
pathways. Third, a rationale for the combination of TOP1 inhibitors with other 
drugs or biological treatments on the basis of the molecular network of individual 
tumours is needed. And fourth, reliable, sensitive and non-invasive biomarkers are 
required to follow the early response or lack of response to TOP1 inhibitors in 
combination with other treatments so that therapies can be rapidly and effectively 
adapted. 
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2. AIM OF THE WORK 
 
Previous  studies in our lab (Crescenzi et al. 2005) had reported that 
Roscovitine was able to modulate DNA repair and senescence. In particular it was 
demonstrated that Roscovitine reinforces doxorubicin (topoisomerase II inhibitor) 
- dependent G1 checkpoint in A549 (lung) and HEC1B (endometrium) leading to 
decreased frequency of double strands breaks and enhanced clonogenic survival. 
However Roscovitine dramatically sensitized other tumour cell lines, such as 
HCT116 (colon) and H1299 (lung) to doxorubicin. Roscovitine, negatively 
affecting DNA repair processes, appear to have the potential to inhibit recovery of 
damaged tumor cells after doxorubicin. However in some tumor cells, the cell 
cycle inhibitory effect of Roscovitine prevails over the DNA repair inhibitory 
effect favouring the clonogenic growth. These observations prompted us to 
investigate the effects of Roscovitine in combination with another chemotherapic 
compound namely Camptothecin. This drug is also a  Topoisomerase inhibitor but 
is selective for topoisomerase I. Since Topoisomerase I  specifically binds single 
strand DNA, Camptothecin at variance with Doxorubicin is particular active in S 
phase of the cell cycle. This work is then aimed to the clarification of the effects 
of Roscovitine in the modulation of the intra S checkpoint (that the specific target 
of Camptothecin). To this purpose we used two lung cancer cell lines: A549 +/+   
(p53 +/+ ) and H1299 (p53 -/-), a colon cell line (HCT116 p53+/+) and a subclone of 
this one obtained from homologous recombination (HCT116 p53 -/-). 
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3. MATERIALS AND METHODS  
 
3.1 Cell cultures. 
The NCI-H1299 human non–small cell lung cancer cell line was obtained 
from American Type Culture Collection (Rockville, MD). They were cultured in 
RPMI 1640, 2 mmol/L L-glutamine, 10 mmol/L HEPES, 1 mmol/L sodium 
pyruvate, 4,500 mg/L glucose, 1,500 mg/L sodium bicarbonate, 100 Mg/mL 
streptomycin, 100 units/mL penicillin, and 10% FCS. The NCI-H1299 cells are 
p53-/-. 
The NCI-A549 human non–small cell lung cancer cell line was obtained 
from American Type Culture Collection (Rockville, MD). They were cultured in 
Ham’s F12K, 2 mmol/L L-glutamine, 1,500 mg/L sodium bicarbonate, 100 
units/mL penicillin and 10% FCS. All media and cell culture reagents were 
purchased from Life Technologies (San Giuliano Milanese, Italy). The NCI-A549 
cells are p53 +/+.  
The NCI-HCT116 cells human colon cancer  cell line was obtained from 
American Type Culture Collection (Rockville, MD). They were cultured in 
McCoy’s 5A, 2 mmol/L L-glutamine, 100 units/mL penicillin and 10% FCS. 
Cell culture media and reagents were purchased by Invitrogen (San Giuliano 
Milanese, Milan, Italy).  
 
3.2 Drugs treatments. 
Camptothecin (Calbiochem, San Diego, CA) supplied as powder was 
dissolved in sterile water to a final 20 mM stock solution. Roscovitine 
(Calbiochem) was dissolved in DMSO to a final 5 mg/mL stock solution. Cells 
were incubated with Camptothecin (0.5 µM), Roscovitine (10µM) or both for 
48hours, then washed in PBS 1X solution and analyzed (cell cycle, viability and 
clonogenic assay, protein extraction). 
 
 
3.3 Colony forming efficiency assay. 
Cells were plated in triplicate at 2 X 104 per well in a 6-well plate. After 16 
hours, cells were treated with Camptothecin (0.5 µM or Camptothecin plus 
Roscovitine (10 µmol/L),  or DMSO (vehicle). Cell number was assessed using a 
hemocytometer. After 8 to 10 days, colonies (>50 cells) were stained with 1% 
methylene blue in 50% ethanol. 
 
3.4 Flow Cytometry. 
Dishes (10 cm) containing 4 x 105 H1299/A549/HCT116 cells were  
incubated for 24 hours at 37 ° C in 7 mL complete medium  (controls) or in 
medium supplemented with Camptothecin alone or associated with Roscovitine 
for 48 hours. Cells were washed twice with PBS 1X and then detached from the 
dishes by trypsinization, suspended in serum rich medium, centrifuged, washed 
twice with 1 mL PBS, and resuspended for storage (20°C) in 95% ethanol.  Before 
analysis, fixed cells were washed twice, centrifuged, and resuspended in 1 mL 
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PBS containing 1 µg  RNase and 100 µg propidium iodide (Crescenzi et al 2004). 
Samples were  stored in the dark for 20 minutes at room temperature before final 
readings. The cellular orange fluorescence of  propidium iodide was detected in a 
linear scale using a flow cytometer (FACScan, Becton Dickinson, Mountain  
View, CA) equipped with an excitation laser line at 488  nm. About 30,000 events 
(i.e., fluorescence readings,  corresponding to not less than 20,000 cells) were 
recorded  for each sample. The cell cycle was examined after monotherapy and 
combined treatment at the indicated  times. Data were analyzed with ModFit/LT  
(Verity Software, Topsham, ME).  
 
3.5 Immunofluorescence microscopy 
Cells were grown on to gelatin-treated glass coverslips in 60 mm dishes, and 
were allowed to adhere for 48 h. Cells were fixed with ice-cold methanol and 
permeabilized with 0.2% Tween 20 in TBS. Cells were blocked with 10% FBS in 
TBS-T buffer [Tris-buffered saline (TBS) containing 0.1% (v/v) Tween 20] for 15 
min. Bcl-2 was detected by incubating the cells with anti-PCNA monoclonal 
antibody at a dilution of 1:200 for 1 h. Cells were washed with TBS-T and then 
incubatedwith a 1:200 dilution of fluorescein-tagged goat anti-mouse secondary 
antibody (Santa Cruz Biotechnology). After washes with TBS-T, the coverslips 
were mounted on to a microscope slide using a 90% solution of glycerol in TBS 
and analysed with a Zeiss Axioplan2microscope. 
 
3.6 Flow cytometry for γ−H2AX or phospo (ser/thr) ATM/ATR 
substrates. 
Cells were fixed with ethanol and routinely kept at -20°C overnight. Cells 
were washed twice with TBS and permeabilized with TBS, 4% fetal bovine 
serum, 0.1% Triton X-100 for 10 minutes on ice. Cells were washed with TBS 
and incubated with anti-γ−H2AX monoclonal antibody (JBV301) (Upstate 
Biotechnology Milton Keynes, United Kingdom) or monoclonal anti- phospo 
(ser/thr) ATM/ATR substrates antibody (2851) (Cell Signaling technology INC) 
in a 1:200 dilution in TBS, 4% fetal bovine serum, for 2 hours. Cells were washed 
twice with TBS-0.1% Tween 20 and incubated with 1:200 dilution of fluorescein-
tagged goat anti-mouse secondary antibody. After washes with TBS-0.1% Tween 
20, cells were resuspended in TBS and analyzed using a using a flow cytometer 
(FACScan, Becton Dickinson, Mountain  View, CA). Data were analyzed with 
ModFit/LT  (Verity Software, Topsham, ME).  
 
3.7 Western Blot Analysis  
Total cell protein preparations were obtained by lysing cells in 50 mmol/L 
Tris (pH 7.5), 100 mmol/L NaCl, 1% NP40, 0.1% Triton, 2 mmol/L EDTA, 10 
Ag/mL aprotinin,  and 100 Ag/mL phenylmethylsulfonyl fluoride. Protein 
concentration was routinely measured with the Bio-Rad protein assay (Bradford 
M. 1976). Polyacrylamide gels (10%–12%-15%) were prepared essentially as 
described by Laemmli (Laemmli 1971). Molecular weight standards were from 
New England Biolabs (Beverly, MA).Proteins separated on the polyacrylamide 
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gels were blotted onto nitrocellulose filters (Hybond-C pure, Amersham Italia, 
Milan, Italy). Filters were washed and stained with specific primary antibodies 
and then with secondary antisera conjugated with horseradish peroxidase (Bio-
Rad; diluted 1:2,000). Filters were developed using an electrochemiluminescent 
Western blotting detection reagent (Amersham Italia). The anti  Bax (N-20), 
p21CIP1 (C-19), CDK2 (M2), total p53 (DO-1), Cdc25A (F-6), PCNA (PC-10), 
Cdc6 (180.2), chk1 (FL-476), chk2 (H30C), actin (I-19) antibodies were 
purchased from Santa Cruz Biotechnology; anti-pRb (554136) was from BD Phar-
Mingen (Franklin Lakes, NJ); antibodies specific for the phosphorylated state of 
ser345 in chk1, thr68 in chk2 and for ATM/ATR phosphorylated substrates were 
from Cell Signaling Technology (Danvers USA); anti-γ-H2AX (JBW301) was 
from Upstate Biotechnology.(Milton Keynes, United Kingdom);  
 
3.8 Thymidine Incorporation 
Thymidine incorporation experiments were performed in 24-well plates. In 
brief, cells (3 X 104 cells/well) were incubated at 37°C in 2 ml complete medium 
(controls) or medium supplement with Camptothecin (0.5 µM), Roscovitine 
(10µM), or both. All samples were run in triplicate. After 4 h or 48h incubation, 
each well was washed with 1 ml warm medium. the medium was replaced (all 
samples) with fresh culture medium containing labelled [3H]thymidine (0.5 
ACi/ml; Amersham, Buckinghamshire,UK). After 4 h at 37°C, incorporation was 
blocked by extensive washing with warm serum-free medium. NaOH (0.1 M) was 
added to all wells (1 ml) and the plates were left at 37°C for 1 h under constant 
agitation. 10 mL of solutions were used to measure protein concentration by 
routinely measure with the Bio-Rad protein assay (Bradford M. 1976). and the 
remainder was used to measure the incorporated thymidine with the 
semiautomatic Harvester 96 (Skatron Instruments, Lier, Norway). Thymidine 
counts were expressed as a fraction of counts found in controls. 
 
 
3.9 Fractioned proteins extraction 
To isolate chromatin-bound proteins cells were cultured in 100-mm plates, 
washed three times with ice-cold PBS, collected in 1 ml of PBS by scraping, and 
pelleted by quick spinning at 1,000 rpm for 1 to 2 min. Soluble proteins were then 
extracted with ice-cold 0.1% Triton X-100 in CSK buffer for 20 min at 4°C. The 
insoluble, chromatin bound fraction was then pelleted by low-speed centrifugation 
at 3,000 rpm for 5 min at 4°C. These pellets were then reextracted by incubating 
in CSK buffer and collected by centrifugation at 3,000 rpm for 10 min at 4°C. The 
final pellet fraction (containing chromatin-bound proteins) or total cell pellets 
were solubilized in radioimmunoprecipitation assay (RIPA) buffer and equal 
protein was resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis (PAGE). 
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3.10 Senescence-associated β-galactosidase activity.  
Staining for SA-β-gal was done as described previously (Dimri 1995 ). 
Routinely, cells were treated with Camptothecin or Camptothecin plus 
Roscovitine for 48hours, then washed exensively, trypsinized and  plated in 
triplicate dishes  at 1 x 105 in 60-mm dishes. The assay was performed 8 to 10 
days after. 
 
3.11 Statistical analysis  
All the data were expressed as mean+/- SD.  Significance was assessed by 
Student τ-test for comparison between two means. P values of less than 0.05 were 
considered statistically significant.   
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4. RESULTS AND DISCUSSION  
 
4.1 Roscovitine increases cell recovery after drug release from 
Camptothecin 
 
Camptothecin is a widely used chemotherapeutic compound and its effect is 
due to accumulation of DNA DSBs. Deficiencies in both the checkpoint and 
DNA-repair pathways determine cellular sensitivity to TOP1 inhibitors. The 
identification of such defects in tumours should address guide the rational use of 
TOP1 inhibitors. Targeting checkpoint and repair pathways will results in 
increasing the selectivity of TOP1 inhibitors in tumours that have pre-existing 
deficiencies in relevant redundant pathways. Therefore, defects in cell-cycle 
checkpoints might adversely affect DNA repair and increase the antiproliferative 
activity of Camptothecin. 
The abrogation of cell-cycle checkpoints can be achieved using small-
molecule inhibitors of the protein kinases, such as CHK1, CHK2, ATM, ATR, 
DNA-PK and CDKs. 
We chose to investigate the effects of the specific combination of 
Camptothecin and Roscovitine, a CDKs inhibitor. Hence we incubated A549 and 
H1299 cell lines for 48 hours either with Camptothecin alone or in combination 
with Roscovitine. The dose of Camptothecin used (0.5 µMol) was assessed to not 
induce a remarkable apoptotic process because the absence of a sub-G1 
population (Fig.8). The dose of Roscovitine (10mM), instead was already 
demonstrated to not induce cell death but only inhibit cell proliferation (Crescenzi 
2005). After the treatment cells were released and recultured in drug free medium 
for 8 to 10 days to investigate the effect of Roscovitine  on clonogenic survival. 
These experiments surprisingly showed a significant increase in colony formation 
in the presence of Roscovitine if compared to the single treatment with 
Camptothecin alone (Fig. 7). This effect was verified as in A549 cells as in H1299 
cells. This result was in some way similar to that obtained by Crescenzi et al. in 
2005. They demonstrated that Roscovitine was able to protect A549 cells exposed 
to a sublethal dose of DNA-damaging agent resulting in a chemoprotective effect 
against doxorubicin.  For H1299 cells, instead the effect verified by the authors 
was different. They underlined the ability of Roscovitine to potentiate the effect of 
doxorubicin inducing an effect of chemosensibilization. In our system we found 
an opposite effect.  
To verify if Roscovitine was able to induce chemoprotection against 
Camptothecin independently from p53 status of cells we used other cell lines: 
HCT116 (colon cancer) that are p53 wt and a subclone p53 null derived from the 
same line for homologous recombination. In both strains Roscovitine was able to 
induce a significant increase in the number of colonies in comparison to those 
obtained after the treatment with Camptothecin alone. (Fig.7) This result 
suggested that the effect of Roscovitine was p53 independent because it was 
similar in all the cell lines analyzed.   
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Fig.7 Clonogenic survivor. Triplicate samples of A549, H1299, HCT116 cells were 
incubated either with Camptothecin (Cpt) or with Camptothecin + Roscovitine (R) for 48 hours. 
Cells were replated in drug-freemedium. After 8 days, colonies were stained with methylene blue. 
P < 0.05, unpaired Student’s t test. 
 
4.2 Roscovitine renforces G1 and intra S checkpoints in Camptothecin-
treated cells. 
To determine the effect of Roscovitine and Camptothecin on cell 
distribution, cells were treated with individual drugs or with their combination and 
analyzed by flow cytometry. (Fig.8)  
In all cell lines Roscovitine alone only slightly affected cell cycle inducing a 
modest but significant increase in G2 fraction as already described before 
(Crescenzi 2005) in all the cell lines analyzed. This increment is perhaps due to an 
apparent slowdown of the cell cycle without a significant effect on cell viability.  
Incubation with Camptothecin 0.5 µM resulted in accumulation of cells in 
different phases of cell cycle that depends on the to p53 status. In fact, p53 
positive cells (A549 and HCT116 wt) showed a block in S phase, instead p53 
negative cells (H1299 and HCT116 p53-/-) accumulated in G2/M phase. This was 
likely due to activation of intra S phase checkpoint in the presence of a functional 
p53 protein or in a more delayed  activation of G2/M checkpoint where p53 is 
absent (Chen et al. 2003). In turn the accumulation of cells in G2-M or S phase, 
instead, was reduced in cells treated with Camptothecin plus Roscovitine and was 
accompanied by a concomitant increase of cells in G1 phase. Increased number of 
G1 cells in combined treatment indicates a reinforcement of G1 checkpoint as 
already described in our laboratory (Crescenzi et al 2005).    
The protective effect of Roscovitine is related to a cell cycle inhibitory 
function, which results in an increased cell cycle block at G1 phase. G1 arrest has 
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been associated previously with decreased susceptibility to chemotherapeutic 
drugs (Sugiyama 1999; Lu 2000). 
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Fig. 8 Cell cycle distribution after single and combined treatments. Cells were incubated with 
Roscovitine, Camptothecin, or both for 48 hours. Percentage of cells in G1, S, or G2-M phase are 
indicated in table.  
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4.3 Cell cycle proteins expression in Camptothecin – Roscovitine treated 
cells 
The ability of Roscovitine to modulate G1 and intra S cell cycle checkpoint 
might either depend on a direct inhibition of CDK activity or on the modulation of 
cell cycle inhibitory proteins. 
To discriminate between these two possibilities, We examined the levels of 
cell cycle regulatory proteins by Western blot in all the cell lines.  Incubation of 
p53 positive cells with the two drugs alone or in combination affects the level of 
expression of the protein and the phosphorylation in Ser 15 as determined with a 
specific antibody. In particular the total level of expression of the protein in A549 
cells results downregulated in the combined treatment (Fig. 9A) if compared to 
Camptothecin alone. This effect is not demonstrable in HCT116 cells. However 
the effect of different treatments on the phosphorylation of Ser 15 in both cell 
lines is quite interesting. In fact it is induced upon treatment with Camptothecin 
alone and is significantly reduced upon combined treatment The tumor suppressor 
p53 is known to play a key role in cell cycle arrest as well as apoptosis in response 
to various stresses such DNA-damaging agents and anticancer drugs. 
Phosphorylation of p53 on Ser15 by the phosphatidylinositol-3-like kinases ATM 
and ATR triggers post-translational modifications that contribute to p53 
stabilization (Banin et al. 1998; Canman et al., 1998) and subsequent activation. 
One of the major phosphatidylinositol-3 kinases that target p53 N-terminal residue 
Ser15 for phosphorylation is ATM (Yu et al. 2002). This observation may indicate 
that the presence of Roscovitine affects, in some way, the signalling ATM/ATR 
mediated. To verify this hypothesis we also investigated the levels of proteins that 
are downstream in p53 pathway. In particular we operated Western blot analyses 
of p21 protein and Bax protein. The levels of p21 protein are reduced in the 
presence of Roscovitine if compared with those observed with Camptothecin 
alone. This is detectable in all the cell lines used but is more significant in p53 
negative cells (i.e. H1299 and HCT116 p53 -/-). As already described by Dai and 
al. (2006) the downregulation of p21 is a consequence of CDK inhibitors and may 
change cellular response to chemotherapy. 
According to our observation that cells treated with the combination of the 
two drugs were able to form more colonies than those treated with Camptothecin 
alone, the expression of Bax, a well known proapoptotic protein decrease when 
cells are treated with Camptothecin in the presence of Roscovitine. The 
downregulation of bax is observable in  all the cell lines.   
Because pRb plays a key role in G1 checkpoint (Bartek et al. 2001) and is 
also required for intra-S response to DNA damage (Knudsen 2000; Bosco 2004 ), 
we analyzed pRb phosphorylation status in A549, H1299, and HCT116 cells. An 
accumulation of hypophosphorylated, active pRb was  detected in A549 and 
HCT116 p53+/+ cells incubated with Camptothecin or with Camptothecin plus 
Roscovitine (Fig.9A e B). In contrast, no variation in pRb phosphorylation pattern 
was observed in both H1299 and HCT116 p53-/- after treatment with 
Camptothecin, Roscovitine or their combination (Fig 9A e B). 
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To check other proteins whose levels could have been regulated by 
Roscovitine or Camptothecin (such as Cdc2, Cdc25A and CDK2) we investigated 
their expression. Indeed none of these proteins appeared to have a role in this  
experimental system and their levels remained constant in all experimental 
conditions. Only Cdc25A resulted slightly downregulated in p53 positive lines in 
the presence of Roscovitine. These data suggest that the ability of Roscovitine to 
reinforce G1 and intra S  checkpoint depends on direct inhibition of CDKs.                    
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Fig. 9A e B Cell cycle proteins expression. A549, H1299 (panel A) and HCT116 cells 
(panel B) were incubated with roscovitine (R), Camptothecin (Cpt), or both (Cpt+R) for 48 hours 
and protein expressionwas detected by Western Blot. Filters were probed with anti-α-actin 
antibodies as loading control. 
 
4.4 Roscovitine decreases Camptothecin-induced premature senescence  
To evaluate the ability of Roscovitine to modulate cellular responses to 
Camptothecin, A549, H1299 and HCT116 cells were incubated for 48 hours either 
with Camptothecin alone or in combination with Roscovitine. Cells were then 
released and recultured in drug-free medium for 8 days. Treatment of cells with 
Roscovitine plus Camptothecin decreased the fraction of  senescent cells (βgal-
positivity or flatten morphology) by 40% compared with Camptothecin alone 
(Fig.10). The lower percentage of senescent cells correlates with the decreased 
level of p21 protein in the combined treatment in comparison to that of  
Camptothecin alone. Camptothecin is able to induce cellular senescence either in 
p53 positive and in p53 negative cell lines. It was extensively described that 
chemotherapeutic compounds used at sublethal doses can induce replicative 
senescence in tumour cell lines. In the presence of functional p53 the inhibition of 
Topoisomerase I leads to  the activation of the G1/S checkpoint  p53 dependent, 
block of cell cycle progression  and induction of a replicative senescence program. 
Chang-Rung Chen (2005) have demonstrated that the activation of Chk2 by 
phosphorylation of Thr68 (induced in our conditions by Camptothecin treatment 
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in p53 negative cell lines) causes G2/M  phase arrest and cellular senescence in a 
p53 independent manner. 
In the case of combined treatment, the presence of Roscovitine prevents the 
accumulation of p21 and the activation of p53 or Chk2. This results in a lesser 
activation of replicative senescence program in favour of a DNA repair response 
to damage.    
0
5
10
15
A549                                    H1299
Cpt
Cpt+R
0
5
10
15
20
HCT 116 p53 +/+                     HCT 116 p53 -/-
Cpt
Cpt+R
20
 
Fig. 10 Effect of combined treatment on senescence. Triplicate samples of A549, H1299 
and HCT116 cells were incubated either with Camptothecin (Cpt) or with Camptothecin + 
Roscovitine (Cpt+R) for 48 hours. Cells were replated in drug-free medium. After10 days, cells 
were stained to detect SA-β-gal activity. The amount of senescent cells was determined by 
counting of three random fields. Columns, mean of three independent experiments 
 
4.5 Chemoprotective effects of Roscovitine correlate with the extent of 
DNA damage. 
The ability of Roscovitine to reinforce the G1 checkpoint in A549, HCT116 
and H1299 cells is likely to be responsible for the increased resistance of the cells 
to Camptopthecin. To further investigate the mechanism of action of Roscovitine, 
it was examined the incidence of phosphorylation of histone H2AX (-H2AX) in 
Camptothecin / Roscovitine  treated cells. γ-H2AX is a sensitive signal for the 
detection of DNA DSBs (Rogakou et al 1998; Sedelnikova et al. 2002) since the 
amount of phosphorylated H2AX increases linearly with the severity of the 
damage. 
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Cells were incubated either with Camptothecin alone or with Camptothecin 
plus Roscovitine and subsequently analyzed by flow cytometry. Increased 
intensity of fluorescence in Camptothecin-treated cells compared with controls 
was readily detected by flow cytometry (Fig.11) Analyses of γ-H2AX in 
Camptothecin versus Camptothecin plus Roscovitine–treated cells confirmed the 
accumulation of cells with low fluorescence in the presence of Roscovitine. These 
data strongly suggest a chemoprotective effect of Roscovitine in A549, H1299 and 
HCT116 (both p53 wt or p53 -/-) cells.  
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Fig. 11 A e B  Effects of Roscovitine and Camptothecin on H2AX phosphorylation. 
A549, H1299 (panel A) and HCT116 (panel B) cells were incubated with Roscovitine or with 
Camptothecin in the presence or absence of Roscovitine for 48 hours. Cells were immunostained 
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with an anti-γ-H2AX monoclonal antibody followed by secondary fluorescein conjugate antibodies 
and analyzed by flow cytometry. In single panel it is showed the overlay of fluorescence peck of 
Camptothecin versus Camptothecin/ Roscovitine -treated cells. 
 
It was also performed a double cytofluometric analysis of cell cycle by PI 
assay and H2AX phosphorylation evaluation to correlate DNA damage with cell 
cycle phase and induction of apoptosis. In both p53 positive cell lines, the highest 
degree of H2AX phosphorylation induced by Camptothecin alone was seen in S-
phase cells, particularly during early stage of S. In cells not replicating DNA (G1, 
G2 and M) the level of H2AX phosphorylation was markedly lower than that in S-
phase cells. Furthermore, the level of Camptothecin - induced γH2AX in G1 phase 
was much higher if cells were simultaneously contemporary treated with 
Roscovitine. The data are consistent with the notion that H2AX phosphorylation 
observed throughout S phase reflects formation of DSBs due to the collision of 
replication machinery with the complex Camptothecin-topoisomerase stalled on 
DNA. It has been suggested that the stalled replication forks attract cycle sensor 
proteins which trigger the ATR/Chk1- dependent checkpoint signalling cascade 
that involves activation of a variety of proteins including p53. Activated p53 
(phosphorylated by ATR/Chk1 kinases) become stable and is able to arrest cell 
cycle progression, as well as to increase cells apoptosis in response to DNA 
damage (cell cycle 2005) . As already indicated, treatment of A549 and HCT cells 
with Camptothecin results in p53 phosphorylation. Since this phosphorylation 
remarkable decreases in the presence of Roscovitine it appears that the DNA 
damage is repaired more efficiently in this condition while p53 mediated are not 
induced. 
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Fig. 12 Correlation of cell cycle distribution of cells with DNA damage (H2AX 
phosphorylation). It was performed a double cytofluometric analysis of cell cycle by PI assay and 
H2AX phosphorylation evaluation to correlate DNA damage with cell cycle phase and induction 
of apoptosis.  Cells were immunostained with an anti-γ-H2AX monoclonal antibody followed by 
secondary fluorescein conjugate antibodies in the presence of Propidium Iodide and analyzed by 
flow cytometry. Dot plots report PI signal versus fluorescein fluorescence (FITC). 
 
 
 
4.6  ATM/ATR substrates are phosphorylated in Camptothecin/ 
Roscovitine treated cells. 
In order to establish if the chemo-protective effect of Roscovitine against 
Camptothecin was due to a more efficient activation of DNA damage sensors i.e. 
ATM and ATR proteins, the activity of these two proteins in the presence of 
Camptothecin, Roscovitine or both has been evaluated. ATM and ATR kinases 
preferentially phosphorylates the S/TQ motif as a consensus sequence in many of 
substrate proteins such as p53 NBS1, BRCA1, Chk1/Chk2, and SMC1 (Kim, S. 
1999). Consequently it was used an antibody that detects endogenous levels of 
proteins containing the phosphorylated ATM/ATR substrate motif. The assay was 
conducted cytofluorimetrically assay using the indicated antibody and a secondary 
fluoresceinated antibody. Roscovitine alone wasn’t able to efficiently activate 
ATM/ATR in our cells (Fig.13). The treatment with Camptothecin, instead, 
produced an increase in ATM/ATR activity that is underlined by the increase of 
phosphorylation of the consensus motif of the substrates proteins (Fig.13). This 
increment was more evident in cells treated simultaneously with the two drugs. 
This result obtained as in both cancer cell lines may indicate that Roscovitine is 
able to induce a more effective response to damage that Camptothecin caused to 
DNA while activating ATM/ATR dependent DNA repair pathways. 
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Fig. 13 A e B Effects of Roscovitine and Camptothecin on ATM/ATR substrates 
phosphorylation. A549, H1299 (panel A) and HCT116 (panel B) cells were incubated with 
Roscovitine or with Camptothecin in the presence or absence of Roscovitine for 48 hours. Cells 
were immunostained with an anti-S/TQ phosphorylated motif monoclonal antibody followed by 
secondary fluorescein conjugate antibodies and analyzed by flow cytometry. In single panel it is 
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showed the overlay of fluorescence peck of Camptothecin versus Camptothecin/ Roscovitine -
treated cells. 
 
4.7 Checkpoint kinases are involved in the response to Camptothecin 
To further investigate the molecular response to single and combined 
treatments, checkpoint kinases were analyzed by Western Blot. These kinases act 
downstream in ATM/ATR pathway. ATM and ATR phosphorylate and activate 
Chk2 (Chehab et al., 1999; Caspari, 2000; Hirao et al., 2000) and Chk1 (Shieh et 
al., 2000), that, in turn directly phosphorylate serine 20 of p53. The stabilized  p53 
activates its transcriptional activity, leading to increased expression of p21 (Taylor 
and Stark, 2001; Kohn and Pommier,2005). The exposure to various DNA-
damaging agents such as topoisomerase inhibitors rapid activates chk2, indicating 
that this kinase plays a role in cell cycle checkpoints. This has been proved 
directly though studies with dominant-negative Chk2, siRNA-mediated Chk2 
ablation, or intrinsic cellular Chk2 deficiency which indicated the activation of the 
S and G2 checkpoints in response to double-strand breaks in various immortalized 
human cell types (Kwak 2006). The treatment with Camptothecin and Roscovitine 
induces the activation of ATM/ATR pathway and, in consequence, the 
phosphorylation of checkpoint kinases 1 and 2. In p53 positive cell lines (A549 
and HCT116 wt) whichever of Camptothecin or Roscovitine are able to induce an 
increment in the basal level of total chk1 protein (Fig.14) but the two drugs 
display no evident effects on Chk2. In addition Chk1 is phosphorylated on Ser 345 
following Camptothecin or Camptothecin /Roscovitine combined treatment. 
Indeed it is known that a significant fraction of Chk1 is phosphorylated following 
DNA damage induced by a variety of agents including UV light, ionizing 
radiation (IR), reduced DNA ligase activity, and Camptothecin too (Wan et al., 
1999; Walworth and Bernards, 1996. Vertebrate Chk1 is phosphorylated by ATR, 
the ATM- and Rad3-related protein kinase (Zhao and Piwnica-Worms, 2001; Liu 
et al., 2000). This phosphorylation is essential for activation of the protein and 
consequently of S phase checkpoint. Activated chk1 induces prolonged cell cycle 
block to facilitate DNA repair. Apparently this effect is mediated by Cdc25A 
degradation (Lam and Rosen cell cycle 2004). Since its level after Camptothecin 
and Camptothecin/Roscovitine treated p53 positive cells result effectively 
downregulated (fig). In p53 negative cells (H1299 and HCT116 p53-/-) only the 
combination of the two drugs is proficient to induce the upregulation and the 
phosphorylation of Chk1 kinase. In contrast Camptothecin alone induces the 
phosphorylation of Chk2 on Thr68. This site is recognized by ATM and the 
phosphorylation of the protein stimulates its activity. The activation of Chk2 
kinase may cause activate a block of cell cycle in G2/M phase and promote cell 
death after DNA damage. This effect was clearly evident in p53 null cell lines, 
after Camptothecin. The G2/M block is reverted by concomitant use of 
Roscovitine that normalizes cell cycle distribution of cells and favours the 
recovery of G1 and S phases. In this case, probably there is an activation of intra S 
checkpoint that is Chk2 independent and Chk1 dependent.  
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Fig. 14  Western blot analyses of Chk  expression. Cells were incubated with Roscovitine 
(R), Camptothecin (Cpt), or both (Cpt+R) for 48 hours and protein expression was detected by 
Western blot.  
 
4.8  Expression of dominant-negative cyclin-dependent kinase 2 
increases Camptothecin-dependent G2 arrest and inhibits cell recovery after 
drug release. 
Pleiotropic effects of Roscovitine have been reported in human tumor cell 
lines. Roscovitine has been shown to induce nucleolar fragmentation (David-
Pfeuty 1999), p53 nuclear translocation, activation of mitogen-activated protein 
kinase pathway (Whittaker 2004), and inhibition of transcription (Hajduch 1999). 
Because Roscovitine protects H1299 cells against Camptothecin, we decided to 
further investigate the role of CDKs in chemoresistance. In fact the drug effect 
might be due or to the direct inhibition of CDK2 or to another secondary effect. 
We used two tetracycline-inducible clones of H1299 cells expressing a mutant 
dominant negative form of CDK2 (DNK2) (Hu 2001). These clones have already 
been isolated in our laboratory and selected for the expression of low level of 
DNK2 to mimic the effects of low concentrations of Roscovitine. Accordingly, 
induction of DNK2 only slightly affected the cell cycle distribution of 
asynchronously growing H1299 cells (Fig.15 A e B). Expression of DNK2 
reverses the G2 arrest imposed by Camptothecin in both clones (Fig.15 A e B). 
This effect  appears very similar to that obtained upon Roscovitine/Camptothecin 
treatment that results in a normalization of cell cycle distribution profile if 
compared to Camptothecin treatment. More importantly, overexpression of DNK2 
results in the induction of expression of Chk1 protein and in its phosphorylation 
by ATR at the  consensus site (ser 345) as already described in Roscovitine / 
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Camptothecin treated H1299 cells. The effect of Camptothecin alone on 
checkpoint kinases in not induced clones is identical to  that observed in H1299. 
In fact, Chk1 expression is not affected and Chk2 results phosphorylated at ATM 
consensus site (Thr 68) as already described. These data indicate that the 
chemosensitizing effect of Roscovitine, observed in H1299 cells, is mediated via 
CDK inhibition.   
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Fig. 15 Effect of dn-K2 on cell cycle and proteins expression. Two different clones of H1299 
cells expressing a dominant negative form of CDK2 were pretreated (inducted) (i) or not (not 
inducted) (n.i.) with doxycycline for 24 hours and subsequently incubated with Camptothecin for 
48 hours. Cytometric and Western Blot analyses were performed. Filters were probed with anti- α-
actin antibody as loading control. 
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4.9 Roscovitine reduces tritiated thymidine [3H]TTP incorporation of 
Camptothecin treated cells 
We investigated the effect of Camptothecin and Roscovitine on tritiated 
thymidine ([3H]TTP) incorporation. This is a sensitive marker of S phase entrance 
and proliferation rate. After 4 hours of incubation with the two drugs, alone or in 
combination, the incorporation of labelled nucleotide was significantly reduced in  
all cell lines if compared with treated control (Fig 15). This is in accord with a 
presumable effect of block of cell cycle in response to DNA damage. It’s notable, 
however, that in Camptothecin treated cells the percentage of incorporation of 
thymidine was higher than in those treated with the combination 
Camptothecin/Roscovitine. This result is evident as in p53 positive cell lines as in 
p53 negative cell lines. The difference in percentage of incorporation between 
single and combined treatment appears statistically relevant after 4 hours of 
incubation with drugs and it’s sustained up to 48hours although becoming 
progressively smaller. The entrance of Campothecin treated cells in S phase 
presumably requires the replication of a partially damaged DNA. The original 
single strand damages induced by Camptothecin cause the appearance of double 
strand breaks so that cells proceed to G2 phase carrying some damaged DNA. 
This presence induces the activation of G2/M checkpoint. The cell cycle arrest 
promotes the activation of DNA repair or, if not possible, the apoptotic response. 
The simultaneously presence of Roscovitine causes, on the contrary, the activation 
of G1 checkpoint and a reduction rate of S phase entrance (as demonstrated by 
lower tritiated thymidine incorporation). In addition it allows more efficient repair 
of DNA damage before replication. This favours the survival of cells to 
Camptothecin treatment and, as long term effect, enhances the capacity to form  
colonies as compared to cells treated with Camptothecin alone.     
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  Fig. 16 Effects of single and combined treatment on Thymidine Incorporation. Cells 
were incubated complete medium (ctrl) or medium supplement with Camptothecin (0.5 µM), 
Roscovitine (10µM), or both. All samples were run in triplicate. After 4 h or 48h incubation, each 
the medium was replaced  with fresh culture medium containing labelled [3H]thymidine and the 
incorporation was measured after 1hours. Data are expressed as percentages of controls. 
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4.10 Camptothecin increases the amount of proliferating cell nuclear 
antigen (PCNA) loaded onto DNA in a p53 dependent way. 
The observation of the ability of Roscovitine to reduce the entrance in S 
phase prompted us to analyze the effects induced on DNA replication proteins 
and, in particular, to measure the level of chromatin bound PCNA after 
Roscovitine, Camptothecin or combined treatment. Such analysis has been 
performed only in HCT116 cells because these are a good system to investigate 
the role of p53 protein in the molecular response to Camptothecin and 
Roscovitine. Cell extracts were separated in two fractions i.e. detergent soluble 
and chromatin-bound fractions, and analysed by Western blot for the intracellular 
distribution of PCNA after 48 hours of incubation with the two drugs. It appeared  
that the treatment with Camptothecin induces a remarkable increase in the amount 
of PCNA chromatin bound in p53 positive HCT116 cells. This effect in turn was 
undetectable in p53 negative subclone. The simultaneous treatment with 
Roscovitine reported the level of chromatin bound PCNA to that of control. No 
appreciable variations of the levels of PCNA in the different intracellular fractions 
in HCT116 p53-/- cells were detectable independently of the way they were 
treated. The major association of PCNA with DNA was then confirmed by 
immufluorescence assays. HCT116 p53 positive cells incubated for 48h with 
Camptothecin showed a more intense fluorescent signal of PCNA antibody in 
correspondence of chromatin clusters (Fig.16). 
  From the results described above, it seems that, in our system, p53 has a 
role in regulating  PCNA bound to chromatin and this is mediated, probably, by 
p21. In fact recent works indicate that p21 is recruited with PCNA in the sites of 
DNA damage (Perucca 2006).The recruitment of PCNA on chromatin is 
counteracted by Roscovitine. It was suggested by Savio et al (2006) who 
demonstrated that the treatment with Roscovitine induces a disassembly of 
PCNA/chromatin complexes. Indeed, PCNA in the cell is present in multiple 
pools and is located replication sites alone or in complex with other protein such 
as CDK2 (Prosperi 2006), p21 and others. Thus, it is possible that overall levels of 
chromatin- bound PCNA were reduced in comparison with Camptothecin because 
Roscovitine inhibited new origin firing and induced disassembly of PCNA present 
at damaged sites (e.g., histone γ-H2AX foci). In addition the number of these sites 
is reduced as indicated by histone γ-H2AX cytofluorimetric assay (section 4.5). 
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Fig. 17 Intracellular distribution of PCNA in HCT116 p53+/+ Camptothecin treated. 
Cells were immunostained with an anti-g-H2AX monoclonal antibody followed by secondary 
fluorescein conjugate antibodies. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). 
HCT116 cells were incubated with Camptothecin or vehicle (DMSO) for 48 hours and analyzed.  
HCT 116 p53 +/+
HCT 116 p53 -/-
PCNA
HCT 116 p53 +/+
HCT 116 p53 -/-
actin
Ctrl R Cpt Cpt +R
C        N       C      N      C      N     C     N     
 
 
 Fig. 18 Cytosolic and nuclear  localization of  PCNA  after Camptothecin or 
Camptotheci/Roscovitine combined treatment. HCT116 cells were incubated for 48 hours in the 
presence of Camptothecin, Roscovitine or both. Different subcellular fractions: Cytosolic not 
chromatin bound (C) or Nuclear chromatin bound (N) were collected and analyzed. Levels of actin 
were used to normalized the quantity of proteins present in fractions.  
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4.11 Camptothecin induces Cdc6 p53 regulated degradation.  
To further clarify the molecular mechanisms involved in cellular response to 
Camptothecin and Roscovitine, we decided to investigate the effect of drugs on 
Cdc6 levels (nuclear as in the cytosolic) form. To this purpose we evaluated  the 
presence of the protein in the different intracellular fractions in p53 +/+ and p53-/- 
HCT116 cells following single and combined treatments  
Cdc6 is recruited by the origin recognition complex during G1, where it 
serves as a loading factor for the minichromosome maintenance (MCM) complex. 
This pre-replication complex (pre-RC) renders the genome competent for 
replication, that may occur after activation of the complex by cyclin-dependent 
kinases (CDKs) at the onset of S phase. It was already demonstrated that, in 
response to genotoxic stress, the ATM mediated activation of p53 results in the 
upregulation of p21. Duursma et al. demonstrated that the accumulation of this 
CDK inhibitor is necessary for Cdc6 degradation which is strictly p53 dependent. 
We found that Camptothecin treatment leads to a downregulation of Cdc6 in 
nuclear and cytosolic fractions analyzed but only in p53 positive line while no 
differences were detectable in HCT p53-/- (Fig. 19). 
The decrease in Cdc6 levels has been strictly related to the induction of 
apoptotic processes. In fact Feng et al in 2003 demonstrated that the inhibition of 
the expression of DNA replication-initiation proteins such as Cdc6, induces 
apoptosis in human cancer cells. It has also been demonstrated that Cdc6 is also 
directly cleaved by caspase3 in ATM/ATR mediated apoptosis (Yim 2006). 
 The combined treatment with Roscovitine abrogates this degradation 
preventing apoptosis. It must be noted that in the presence of Roscovitine there is 
an increase in cytoplasmic, albeit not functional form of Cdc6. The traslocation of 
Cdc6 generally takes place at the onset of S phase (Saha 1998) but, in our 
conditions it is mediated by Roscovitine to probably prevent damaged DNA 
replication. These data are in accord to our hypothesis which consider Roscovitine 
as a factor favouring DNA repair and recovery of cells that, otherwise, are 
committed to apoptosis or senescence.  
Ctrl R Cpt Cpt +R
Cdc6
C       N       C      N      C      N     C     N     
HCT 116 p53 +/+
HCT 116 p53 -/-
HCT 116 p53 +/+
HCT 116 p53 -/-
actin
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Fig.19 Cytosolic and nuclear  localization of  Cdcc6 after Camptothecin or 
Camptothecin/Roscovitine combined treatment. HCT116 cells were incubated for 48 hours in 
the presence of Camptothecin, Roscovitine or both. Different subcellular fractions: Cytosolic not 
chromatin bound (C) or Nuclear chromatin bound (N) were collected and analyzed. Levels of actin 
were used to normalized the quantity of proteins present in fractions. 
 
5. CONCLUSIONS 
Resistance to chemotherapeutic drugs is the most frequent reason for the 
failure of cancer treatments. In this reason new strategies have been developed in 
clinical practice including the use of “combined” regimens of therapy. The 
response of cancer cell lines to the treatment with new compounds or their 
combination may give useful indications for the effective advantage for their use 
in vivo. In this work we tried to better understand molecular and cellular 
mechanisms activated by tumour cells when treated with the combination of two 
chemotherapeutic drugs i.e. Camptothecin (Topoisomerase I inhibitor) and 
Roscovitine (CDK inhibitor). We showed that this particular combination  favours 
cellular surviving compared with the single treatment with Camptothecin alone. 
This effect was p53 independent in fact, although we have used four different 
tumour cell lines having different p53 status they behaved similarly upon the 
various treatments. This was shown by mean of  several approaches including cell 
cycle progression analysis, protein expression evaluation, DNA damage response, 
replicative senescence pathway and cellular proliferation rates. All experiments 
suggested that Roscovitine, by inhibiting CDK and, in particular Cdk2, protects 
cells from Camptothecin induced damage. When in combination Roscovitine, in 
fact, favours a  response of DNA repair rather than apoptosis or senescence 
pathways activation. This effect is due to its capacity to induce 1) an earlier 
activation of cell cycle checkpoints with an increased activity of the damage 
sensor kinases ATM and ATR, 2) a reduction of chemical induced replicative 
senescence 3) a decrease in the amount of DSBs. Roscovitine, in addition, reduced 
thymidine incorporation in Camptothecin treated cells and the amount of 
chromatin bound PCNA. These facts prevent the entrance and progression of cells 
in S phase in the presence of Camptothecin-damaged DNA.  
It’s also clear that p53 plays an important role because its activity is 
regulated indirectly by Camptothecin and Roscovitine. In the presence of the first 
compound p53 is phoshorylated in Ser15 resulting immediately activated. The 
activation causes several effects including p21 is upregulation, cdc6 degradation 
and, at longer times,  triggering of apoptosis. In the presence of Roscovitine p53 
does not result active so there are no further consequences; cells do not undergo 
apoptotic processes, the DNA repair is favoured and there is a rapid recovery from 
damage .  
Our results in whole raise an important question because suggest possible 
dangerous effects deriving from this particular combination of drugs in human 
therapy. 
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The endoplasmic reticulum represents the quality control site of
the cell for folding and assembly of cargo proteins. A variety of con-
ditions can alter the ability of the endoplasmic reticulum (ER) to
properly fold proteins, thus resulting in ER stress. Cells respond to
ER stress by activating different signal transduction pathways lead-
ing to increased transcription of chaperone genes, decreased pro-
tein synthesis, and eventually to apoptosis. In the present paper we
analyzed the role that the adaptor protein tumor necrosis factor-
receptor associated factor 2 (TRAF2) plays in regulating cellular
responses to apoptotic stimuli from the endoplasmic reticulum.
Mouse embryonic fibroblasts derived from TRAF2/ mice were
more susceptible to apoptosis induced by ER stress than the wild
type counterpart. This increased susceptibility to ER stress-induced
apoptosiswas because of an increased accumulation of reactive oxy-
gen species following ER stress, and was abolished by the use of
antioxidant. In addition, we demonstrated that the NF-B pathway
protects cells from ER stress-induced apoptosis, controlling ROS
accumulation.Our results underscore the involvement of TRAF2 in
regulating ER stress responses and the role of NF-B in protecting
cells from ER stress-induced apoptosis.
In eukaryotic cells, proteins must be correctly folded and assembled
before to transit to intracellular organelles and the cell surface (1, 2). A
number of cellular stress conditions can interfere with protein folding,
leading to accumulation of unfolded or misfolded proteins in the endo-
plasmic reticulum (ER)3 lumen. The ER has evolved specific signaling
pathway to deal with the potential danger represented by the misfolded
proteins. This adaptive response is named unfolded protein response
(3). Activation of unfolded protein response results in attenuation of
protein synthesis, and up-regulation of genes encoding chaperones that
facilitate the protein folding process in the ER. Thus, unfolded protein
response reduces accumulation and aggregation of malfolded proteins,
giving the cell the possibility of correcting the environment inside the
ER (3, 4). However, if the damage is too strong and homeostasis cannot
be restored, themammalian unfolded protein response initiates apopto-
sis. In mammalian cells, three transmembrane proteins Ire1 (5), Ire1
(6), and PERK (7) act as ER stress sensor proteins and play important
roles in transducing the stress signals initiated by the accumulation of
malfolded proteins from the ER to the cytoplasm and nucleus. Ire1s and
PERK are kept in an inactive state through association of their N-termi-
nal lumen domain with the chaperone BiP. Following accumulation of
malfolded proteins in the lumen of the ER, BiP dissociates to bind the
malfolded proteins and Ire1s and PERK undergo oligomerization and
transphosphorylation within their cytoplasmic kinase domains (8, 9).
Other stress response pathways are activated following ER stress,
such as the JNK/SAPK andNF-Bpathways (10, 11). Activation of these
pathways following ER stress is mediated by the physical and functional
interaction of Ire1 and TRAF2 (10). The central role played by TRAF2
in mediating cellular response to ER stress has been proposed based
upon the observation that ectopic expression of a dominant negative
mutant of TRAF2 lacking theN terminus Ring finger domain, blocks ER
stress-induced NF-B and JNK/SAPK activation, and that mouse
embryonic fibroblast derived from TRAF2 knock-out mice failed to
activate NF-B following ER stress (10, 11). TRAF2 was initially identi-
fied as a TNF receptor 2 interacting protein (13). Interestingly, TRAF2-
deficientMEFs are very sensitive to cell death induced byTNF andother
members of the TNF receptor family (14, 15). At least part of the anti-
apoptotic effect of TRAF2 can be explained by its function as amediator
of NF-B activation, thus leading to NF-B-dependent expression of
anti-apoptotic genes. The anti-apoptotic activity of NF-B also involves
inhibition of the JNK cascade via at least two distinct mechanisms:
through GADD45--mediated blockade of MKK7 and interference
with ROS production (16, 17). It is well known that ROS or oxidative
stress plays an important role in various physiological and pathological
processes such as aging, inflammation, and neurodegenerative diseases
(18–20). Recently, it has been demonstrated that accumulation of mis-
folded protein within the lumen of the ER causes accumulation of ROS
and cell death (21). However, it is currently unknown whether some of
the key molecules involved in ER stress response, such as TRAF2, are
involved inmodulation of ROS and induction of apoptosis. Here we use
MEFs derived from TRAF2 knock-out mice to study the role of TRAF2
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MIUR-FIRB RBNE0155LB, and Centro di Competenza GEAR. The costs of publication of
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phenyl)-2-(4-sulfophenyl)-2H-tetrazolium; FL, full-length; NAC, N-acetyl-L-cysteine.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 281, NO. 5, pp. 2631–2638, February 3, 2006
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
FEBRUARY 3, 2006 • VOLUME 281 • NUMBER 5 JOURNAL OF BIOLOGICAL CHEMISTRY 2631
 at UNIVERSITA DI NAPO
LI on Novem
ber 28, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
 http://www.jbc.org/cgi/content/full/M502181200/DC1
Supplemental Material can be found at: 
in the regulation of pro-survival or pro-apoptotic pathways following
ER stress.
EXPERIMENTAL PROCEDURES
Cell Culture and Biological Reagents—Wild type (WT) and
TRAF2/murine embryonic fibroblasts (MEFs) were provided byDrs.
T. W. Mak and W. C. Yeh (14). WT and JNK1/2/ and WT and
p65/ MEFs were provided by Dr. R. Davis and Dr. G. Franzoso,
respectively (22, 23). Cells were cultured in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% fetal calf serum, 100
units/ml penicillin, and 100 g/ml streptomycin. Thapsigargin was
from Calbiochem and used at 5–50 nM; tunicamycin was purchased
from Roche and used at 50–150 ng/ml. Dichlorodihydrofluorescein
diacetate (H2DCFDA) (Calbiochem) was dissolved in Me2SO and used
at 5 M; L-NAC was dissolved in sterile water and used at 5 mM. Anti-
TRAF2, anti-IB, and anti-JNK antibodies were purchased from Santa
Cruz Biotechnology. The TRAF2 full-length expression vector was pre-
viously described (24).
Western Blot Analysis—Subconfluent monolayer of murine embry-
onic fibroblasts were washed with phosphate-buffered saline and then
lysed in a lysis buffer containing 20 mM HEPES, pH 7.5, 150 mM NaCl,
10% glycerol, 1% Triton X-100, supplemented with a mixture of prote-
ase inhibitors (Roche). Equal amounts of total proteins (50 g) were
resolved by SDS-polyacrylamide gels. Separated proteins were trans-
ferred to polyvinylidene difluoride membranes (Millipore, Bedford,
MA) at 4 °C for Western blot analysis. Filters were blocked for 1 h at
room temperature with 10% nonfat dry milk in TBS-T buffer (10 mM
Tris-HCl, pH 8, 150 mM NaCl, 0.1% Tween 20). Then, filters were
probed with specific antibodies in the same buffer for 14–16 h at 4 °C.
After TBS-T washing to remove excess primary antibodies, the blots
were incubated in horseradish peroxidase-coupled secondary antibody
for 1 h followed by enhanced chemiluminescence detection of the pro-
teins with Hyper-film ECL detection (Amersham Biosciences).
Luciferase Assay—For luciferase assay, WT, TRAF2/, and
TRAF2FL MEFs (4  105 cells per well) were seeded in 6-well (35 mm)
plates. After 12 h cells were transfected with 0.5 g of Ig-B-LUC
reporter gene plasmid using Lipofectamine. Cells were stimulated with
thapsigargin or tunicamycin for 8 h, and reporter gene activity was deter-
mined by the luciferase assay system (Promega). A pRSV--galactosidase
vector (0.2 g) was used to normalize for transfection efficiencies.
Retroviral Infection—Full-length hemagglutinin-tagged TRAF2 was
subcloned into the retroviral expression vector pBMN by standard
cloning techniques. pBMN vector was then transfected in a packaging
cell line using Lipofectamine. 48 h after transfection, the viral superna-
tants were supplemented with Polybrene (9 mg/ml) and filtered through a
0.45-mm filter. TRAF2/ fibroblasts (1  106) were incubated with viral
supernatants for 48 h. The expression of exogenous proteinwas assayed by
Western blot analysis on total cell extracts using anti-TRAF2 antibodies.
ER Stress Induction and Measurements of Apoptosis—5  103 cells/
well were seeded in 96-well culture plates and incubated for 24 or 48 h at
37 °Cwith different concentrations of thapsigargin or tunicamycin. Cell
survival was examined using 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt
(MTS) and an electron coupling reagent (phenazine methosulfate),
according to the manufacturer’s instructions (Promega). Cell death was
assessed by staining the exposed phosphatidylserine on cell membranes
with fluorescein isothiocyanate-conjugated annexin V (BD Pharmin-
gen), or propidium iodide staining according to Nicoletti et al. (25).
Samples were analyzed by flow cytometry using a FACScalibur (Beck-
man Coulter, Fullerton, CA), equipped with ModFit Software. Results
were mean  S.D. of at least three separate experiments.
Measurement of ROS Production—Reactive oxygen species were
detected with H2DCFDA (Calbiochem). H2DCFDA diffuses into the
cells where it is converted into a non-fluorescent derivative (H2DCF) by
endogenous esterases. H2DCF is oxidized to green fluorescent DCF in
the presence of intracellular ROS. Cells were routinely treated with
either tunicamycin or thapsigargin for 24 or 48 h, washed, and incu-
bated at 37 °C for 30 min in the presence of H2DCFDA in serum-free
medium. Me2SO-treated cells were used as controls. After incubation,
cells were washed twice with phosphate-buffered saline, resuspended in
phosphate-buffered saline, and analyzed by flow cytometry using a
FACScan Cell Scanner (BD Biosciences).
Kinase Assay—JNK immunoprecipitates were used for the immune
complex kinase assay that was performed at 30 °C for 10 min with 2 g
of substrate, 10 Ci of [-32P]ATP in a total of 20 l of kinase buffer (20
mM HEPES, pH 7.4, 10 mM MgCl2, 25 mM -glycerophosphate, 50 M
Na3VO4, and 50 M dithiothreitol). The substrate was glutathione
S-transferase-c-Jun (amino acids 1–79). The reaction was termi-
nated by boiling in SDS sample buffer, and the products were
resolved by 12% SDS-PAGE. Phosphorylated proteins were detected
by autoradiography.
RESULTS
Increased Susceptibility of TRAF2/ MEFs to ER Stress-induced
Apoptosis—TRAF2 is a scaffold protein that transduces signals from
membrane receptors and the ERmembrane (10–12). To assess the role
of TRAF2 in apoptosis induced by ER stress, we treated MEFs derived
fromTRAF2/ mice andWTMEFs with increasing concentrations of
thapsigargin and tunicamycin. Both drugs induce ER stress by inhibiting
ER-resident Ca2-ATPase, and N-glycosylation, respectively. After a
48-h treatment, some morphological changes were observed. In partic-
ular, WT MEFs showed an extended shape, typical of cellular stress
response, whereas TRAF2/ MEFs appeared detached and shrunken
(Fig. 1A). Because these morphological changes were reminiscent of
apoptosis, we performed annexin V staining on WT and TRAF2/
MEFs. As shown in Fig. 1B, treatment with thapsigargin or tunicamycin
caused a dramatic increase in apoptosis in TRAF2/ MEFs but not in
WT MEFs. The higher sensitivity to apoptosis observed in TRAF2/
MEFs was not because of an intrinsic defect of these cells, given that
reintroduction of TRAF2 (TRAF2FL) completely rescued cell viability
(Fig. 1, C–E). TRAF2/ MEFs showed the same susceptibility as WT
MEFs to serum starvation- and doxorubicin-induced cell death (Fig.
1F). These results suggest a specific role for TRAF2 in modulating sur-
vival signals from the ER.
ROSMediate Increased Apoptosis in TRAF2/MEFs—ER stress has
recently been shown to promote oxidative stress and apoptosis (21).
Hence, to have some insight on the molecular mechanism determining
the increased susceptibility to ER stress-induced apoptosis, we com-
pared ROS production inWT andTRAF2/MEFs. As shown in Fig. 2,
treatment with thapsigargin or tunicamycin caused an increase in ROS
production in TRAF2/ MEFs but not inWT. Reconstitution of these
cells with TRAF2 (TRAF2FL) blocked ROS accumulation following
treatmentwith thapsigargin and tunicamycin (Fig. 2,A andB). To inves-
tigate whether the increased production of ROS was responsible for the
susceptibility of TRAF2/ MEFs to ER stress-induced apoptosis,
TRAF2/ MEFs were treated with thapsigargin or tunicamycin in the
presence of different antioxidants and 48 h later cell viability was meas-
ured by MTS assay and the ROS level by flow cytometry. As shown in
Fig. 3, NAC abolished ROS accumulation and protected these cells from
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FIGURE 1. ER stress causes apoptosis in TRAF2/ MEFs. A, WT and TRAF2/ MEFs were treated with 100 ng/ml tunicamycin or vehicle for 48 h. Cell death was examined by
morphological changes under a phase-contrast microscope. B, WT and TRAF2/ MEFs were treated with 5 nM thapsigargin or 50 ng/ml tunicamycin for 48 h. Apoptosis was
assessed by flow cytometry after staining with fluorescein isothiocyanate-conjugated annexin V. Percentage of the apoptotic cell is indicated. C, restoration of TRAF2 protein
expression. TRAF2/ MEFs were infected with an expression vector encoding full-length TRAF2. Expression of the TRAF2 protein was assessed by Western blot in WT,
TRAF2/, and TRAF2-reconstituted cells (TRAF2FL). D, restoration of TRAF2 protein expression rescues TRAF2/ cells from ER stress-induced apoptosis. WT, TRAF2/, and
TRAF2FL MEFs were treated with Me2SO (Co), tunicamycin (Tun), or thapsigargin (Thaps) for 48 h. Cell viability was assessed by MTS assay. Data are mean  S.D. from five
independent experiments. Statistical analysis was by unpaired Student’s t test: **, p  0.002; ***, p  0.0001. E, restoration of TRAF2 protein expression rescues TRAF2/ cells
from endoplasmic reticulum stress-induced apoptosis. TRAF2/, WT, and TRAF2FL MEFs were treated with Me2SO (Co), 20 nM thapsigargin, or 150 ng/ml tunicamycin for 48 h
and analyzed by flow cytometry. Percentage of sub-Go cells is indicated. F, TRAF2
/ and WT MEFs were serum starved for 24 and 48 h, or treated with 0.2 M doxorubicin for
24 and 48 h, and cell viability was assessed by MTS assay. Data are mean  S.D. from three independent experiments. Statistical analysis was by the unpaired Student’s t test:
**, p  0.002; ***, p  0.0001. KO, knock-out.
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apoptosis. Similar results were obtained by using dithiothreitol as anti-
oxidant (data not shown). Interestingly, also the small percentage ofWT
MEFs and reconstituted TRAF2/ MEFs undergoing apoptosis fol-
lowing treatment with tunicamycin and thapsigargin were almost com-
pletely protected by both antioxidants (Fig. 3 and data not shown).
These results demonstrated that susceptibility of TRAF2/ MEFs to
ER stress-induced apoptosis was because of increased accumulation of
ROS. It is worth noting that in TRAF2/ cells, higher levels of ROS and
apoptosis were detected, even in the absence of ER stressing agents (Fig.
1, B and E, and data not shown).
TRAF2-mediated NF-B Activation Protects Cells from ER Stress-
induced Apoptosis—Given the central role played by TRAF2 to cor-
rectly signal activation of NF-B and JNK from ER, we investigated
which of these pathways control ROS accumulation and protect cells
from ER stress-induced apoptosis. MEFs derived from p65 knock-out
and JNK1/2 double knock-out mice were treated with thapsigargin or
tunicamycin in the presence or absence of NAC. As shown in Fig. 4A,
p65/ MEFs showed very high levels of ROS following treatment with
thapsigargin and tunicamycin. As expected, treatment with NAC
decreased ROS accumulation by about 40%. In contrast, JNK1/2/
MEFs showed an accumulation of ROS similar to WT MEFs (Fig. 4A).
Statistical analysis is reported in Fig. 4B. We next investigated the sus-
ceptibility of p65/ and JNK1/2/ MEFs to apoptosis induced by
thapsigargin or tunicamycin in the presence or absence of NAC. As
shown in Fig. 4C, p65/ MEFs were highly susceptible to apoptosis
compared with WT MEF and treatment with NAC significantly
increased cell viability. JNK1/2/ MEFs did not show susceptibility to
ER stress-induced cell death, as compared with WT MEFs. These
results suggest that NF-B protects cells from ER stress-induced apo-
ptosis by controlling ROS accumulation.
FIGURE 2. Susceptibility of TRAF2/ MEFs to
endoplasmic reticulum-dependent oxidative
stress. A, WT, TRAF2/, and TRAF2FL MEFs were
treated with Me2SO (Co), 20 nM thapsigargin
(Thaps), or 150 ng/ml tunicamycin (Tun) for 24 or
48 h. Cells were labeled with 5 M H2DCFDA and
analyzed by flow cytometry. B, Kolmogorov-Smir-
nov statistical analysis of flow cytometric data
were used according to Cell Quest Software (BD
Biosciences Immunocytometry Systems). D values
by Kolmogorov-Smirnov analysis (p  0.001) are
shown.
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FIGURE 3. ROS production correlates with endoplasmic reticulum stress-induced apoptosis. WT, TRAF2/, and TRAF2FL MEFs were treated with Me2SO (Co), 150 ng/ml
tunicamycin (Tun), or 20 nM thapsigargin (Thaps) for 48 h, in the presence or absence of antioxidants (NAC or dithiothreitol). ROS production was assessed by flow cytometry after
labeling with H2DCFDA. Cell viability was evaluated by MTS assay. Data are mean  S.D. from three independent experiments. Statistical analysis was by the unpaired Student’s t test:
*, p  0.02; **, p  0.002; ***, p  0.0001.
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FIGURE 4. Differential susceptibility of p65/ and JNK1/2/ MEFs to endoplasmic reticulum-dependent oxidative stress. A, JNK1/2/ and p65/ MEFs were treated with
Me2SO (Co), 20 nM thapsigargin (Thaps), or 150 ng/ml tunicamycin (Tun) for 24 h, in the presence or absence of 5 mM NAC. ROS production was assessed by flow cytometry after
labeling with H2DCFDA. B, Kolmogorov-Smirnov statistical analysis of flow cytometric data were used according to Cell Quest Software (BD Biosciences). D values by Kolmogorov-
Smirnov analysis (p  0.001) are shown. C, p65/ and JNK1/2/ MEFs were treated with Me2SO (Co), thapsigargin (Thaps), or tunicamycin (Tun) for 24 h, in the presence or absence
of 5 mM dithiothreitol. Cell viability was evaluated by MTS assay. Data are mean  S.D. from three independent experiments. Statistical analysis was by the unpaired Student’s t test:
*, p  0.02; **, p  0.002. KO, knock-out.
TRAF2 Regulates ER Stress-induced Apoptosis
2636 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281 • NUMBER 5 • FEBRUARY 3, 2006
 at UNIVERSITA DI NAPO
LI on Novem
ber 28, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
To have further insight on the cross-talk between the NF-B and the
JNK pathways after ER stress, we evaluated activation of both pathways
inWT, TRAF2/, and reconstituted TRAF2FLMEFs. Treatment with
tunicamycin caused activation of NF-B inWT andTRAF2FLMEFs, as
demonstrated by the disappearance of the inhibitory subunit IB (Fig.
5A) and by the increased activity of a B-driven luciferase reporter gene
(Fig. 5B). In the absence of TRAF2 it was not possible to detect activa-
tion of NF-B. The observed activation of NF-B was functional as
demonstrated by the reappearance of the inhibitory subunit IB, a
known early target gene of NF-B (Fig. 5A).
Activation of JNK in WT and TRAF2FL MEFs stimulated with
tunicamycin was detected 90 min after stimulation and decreased
thereafter. Treatment with antioxidant did not affect JNK activation
(Fig. 6). In contrast, in TRAF2/ MEFs, activation of JNK was
detectable only 6 h after stimulation and remained sustained for up
to 12 h. This sustained activation of JNK was almost completely
suppressed by NAC (Fig. 6). This result confirms that TRAF2 was
necessary to activate JNK after ER stress, and suggests that the
increased level of ROS detected in the absence of TRAF2 may mediate
the sustained activation of JNK. This is in agreement with previous
reports showing that after TNF stimulation the early activation of JNK
depends on TRAF2 and that the sustained activation of JNK depends on
ROS (26). Altogether these results suggested that following ER stress,
the TRAF2-mediated activation of NF-B was responsible for protec-
tion from apoptosis by decreasing ROS levels and controlling sustained
JNK activation.
DISCUSSION
The endoplasmic reticulum is the principal site for protein synthesis
and folding, and also serves as a cellular storage site for calcium. Agents
that interfere with protein folding or export lead to ER stress and even-
tually cell death. Although initiation of apoptosis induced by death
receptors andmitochondria is well studied, themechanismbywhich ER
stress triggers apoptosis is still not clear. In the present paper, we pres-
ent evidence supporting a central role played by TRAF2 in regulation of
pro-apoptotic and anti-apoptotic pathways initiated at the ER.Wedem-
onstrate that TRAF2/ MEFs have increased susceptibility to ER
stress-induced apoptosis. This increased susceptibility to ER stress-in-
duced apoptosis was because of accumulation of ROS following ER
stress, and was abolished by the use of antioxidants, such as NAC. In
addition, we demonstrated that NF-B was protecting cells from ER
stress-induced apoptosis by controlling ROS accumulation.
TRAF2 has been demonstrated to be involved in signaling from endo-
plasmic reticulum being able to interact with Ire1 (10), one of the ER
transmembrane proteins involved in initiating signals from the ER.
TRAF2mediates activation of both the JNK/SAPK and theNF-B path-
ways following ER stress (10, 11). This scenario is reminiscent of TNF
signaling, in which TRAF2 mediates simultaneous activation of the
NF-B survival pathway and pro-apoptotic JNKpathway, and the fate of
the cell would be determined by interplay between these opposing sig-
nals. NF-B exerts its anti-apoptotic activity by inhibiting caspase func-
tion (28–30), preserving function of mitochondria (31), and down-reg-
ulating JNK activity (23, 32). The latter function is mediated by at least
two different mechanisms: by blocking activation of MKK7 via
GADD45 (16) and decreasing ROS accumulation via the ferritin heavy
chain (17). The importance of ROS in regulating sustained activation of
JNK followingTNF receptor triggering has been recently investigated in
a NF-B null cell model (26). Based on this study, TRAF-mediated
NF-B activation suppresses the TNF-induced ROS accumulation that,
in turn, induces prolonged JNK activation and cell death. Our result
supports this model and suggests that a similar mechanism may also
operate for the ER. In fact, induction of ER stress causes activation of
both NF-B and JNK. In the absence of TRAF2 or p65, the NF-B
FIGURE 5. Defective activation of the NF-B pathway in TRAF2/ MEFs after endo-
plasmic reticulum stress. A, WT, TRAF2/, and reconstituted TRAF2FL MEFs were
treated with tunicamycin (Tun) (150 ng/ml), and expression of the IB protein was
analyzed by Western blot. Filters were stripped and reprobed with anti--tubulin
antibodies, as loading control. B, relative luciferase activity observed in WT,
TRAF2/, and TRAF2FL MEFs transfected in triplicate with 0.5 g of the Ig-B-
luciferase reporter plasmid, stimulated with thapsigargin or tunicamycin, as indi-
cated. Values shown (in arbitrary units) represent the mean (S.D.) of two independ-
ent experiments, normalized for -galactosidase activity of a cotransfected Rous
sarcoma virus--galactosidase plasmid.
FIGURE 6. Sustained activation of the JNK pathway in TRAF2/ MEFs after endo-
plasmic reticulum stress. WT, TRAF2/, and TRAF2FL MEFs were treated with tunica-
mycin (150 ng/ml) for the indicated periods of time in the presence or absence of the
antioxidant NAC, and activity of endogenous JNK was assessed by kinase assay using
glutathione S-transferase-c-Jun as substrate. Lower panel shows a Western blot for total
JNK. WB, Western blot.
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pathway is not activated, and the late, ROS-dependent JNK activity is
not counteracted, leading to cell death.
How does ROS affect JNK activation? ROSmay affect JNK activation
by at least two different mechanisms: by oxidizing and inhibiting mito-
gen-activated protein kinase phosphatase (33) and activating the pro-
tein ASK1 (34). This kinase may be activated via ROS and TRAF2 and
has been demonstrated to be essential for inducing cell death after ER
stress, at least in neuronal cells (34, 35). It may be possible that after ER
stress and in the absence of a functional NF-B activation, ASK1 is
activated by the increased level of ROS and mediates sustained JNK
activation and cell death.
Whereas it is clear from our results that the presence of a functional
NF-B is necessary for survival, counteracting increased induction of
ROS following ER stress, the mechanism by which NF-B exerts this
function is not fully understood. It has been recently demonstrated that
NF-B up-regulates expression of ferritin heavy chain, an enzyme
involved in ironmetabolism and suppression of ROS accumulation (17).
However, it is possible that in addition to up-regulation of genes
involved in disposal of the ROS,NF-Bmay also control transcription of
genes that suppress production of ROS.
Our results confirm the central role played by TRAF2 in regulating
activation of NF-B following ER stress, and also sheds light on the
functional significance of this activation. Recently, it has been demon-
strated that in addition to the TRAF2-mediated NF-B activation,
another mechanism leading to activation of NF-B following ER stress
might exist. Based on this model, following ER stress, phosphorylation
of eukaryotic initiation factor 2 represses synthesis of the inhibitory
subunit IB, leading to activation of NF-B (36). The two models of
activation of NF-B following ER stress, the TRAF2-mediated and the
eukaryotic initiation factor 2-mediated, are not mutually exclusive. It is
possible that both mechanisms contribute to activate NF-B upon ER
stress. However, whereas the biological significance of the link between
eukaryotic initiation factor 2 phosphorylation and NF-B activation is
not fully understood, the functional significance of TRAF2-mediated
NF-B activation seems to be clear, at least in our experimental system.
In fact, cells lacking TRAF2 or functional NF-B undergo massive cell
death after ER stress.
In conclusion, in the present study we provide evidence, for the first
time, that the adaptor protein TRAF2 plays a central role in regulating
signaling from the ER and that the activation of NF-B, mediated by
TRAF2, protects cells from ER stress-induced apoptosis. Therefore
TRAF2 and NF-B may be potential targets to control ER stress-in-
duced apoptosis.
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